Session » ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 0287

6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0589

A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE

9:00AM-11:00AM: Abstract Number: 0487

A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0228

A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest

9:00AM-11:00AM: Abstract Number: 0171

A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

9:00AM-11:00AM: Abstract Number: 0665

A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody

9:00AM-11:00AM: Abstract Number: 0632

A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study

9:00AM-11:00AM: Abstract Number: 0274

A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab

9:00AM-11:00AM: Abstract Number: 0430

A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0264

A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis

9:00AM-11:00AM: Abstract Number: 0033

A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients

9:00AM-11:00AM: Abstract Number: 0030

A Pathogenetic Model of IgG4-related Disease Developed from Familial IKZF1 and UBR4 Gene Variants

9:00AM-11:00AM: Abstract Number: 0571

A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test

9:00AM-11:00AM: Abstract Number: 0700

A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta

9:00AM-11:00AM: Abstract Number: 0010

A Potential Mechanism for Major Adverse Cardiac Events Associated with JAK Inhibitors: JAK Inhibitor Withdrawal Causes Urokinase Release by Primed STAT Signaling

9:00AM-11:00AM: Abstract Number: 0013

A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0323

A Randomized, Double-blind, Placebo-controlled, Repeat Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP) – Study 304

9:00AM-11:00AM: Abstract Number: 0324

A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (OAKP) – Study 301

9:00AM-11:00AM: Abstract Number: 0554

A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0547

A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells

9:00AM-11:00AM: Abstract Number: 0031

A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes

9:00AM-11:00AM: Abstract Number: 0082

A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model

9:00AM-11:00AM: Abstract Number: 0044

Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis

9:00AM-11:00AM: Abstract Number: 0651

Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry

9:00AM-11:00AM: Abstract Number: 0298

Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0374

Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry

9:00AM-11:00AM: Abstract Number: 0070

Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis

9:00AM-11:00AM: Abstract Number: 0366

Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis

9:00AM-11:00AM: Abstract Number: 0257

Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia

9:00AM-11:00AM: Abstract Number: 0474

Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample

9:00AM-11:00AM: Abstract Number: 0269

Acute Kidney Injury and Plasma Cell-Rich Acute Interstitial Nephritis in VEXAS Syndrome: An Under-recognized Disease Feature

9:00AM-11:00AM: Abstract Number: 0169

Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective

9:00AM-11:00AM: Abstract Number: 0028

Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis

9:00AM-11:00AM: Abstract Number: 0238

Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature

9:00AM-11:00AM: Abstract Number: 0367

Adolescents and Young Adults Taking Methotrexate: Knowledge and Behaviours

9:00AM-11:00AM: Abstract Number: 0187

Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities

9:00AM-11:00AM: Abstract Number: 0362

Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0464

Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine

9:00AM-11:00AM: Abstract Number: 0069

All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome

9:00AM-11:00AM: Abstract Number: 0363

Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort

9:00AM-11:00AM: Abstract Number: 0697

Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 0018

Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 0677

Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan

9:00AM-11:00AM: Abstract Number: 0577

Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0202

Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)

9:00AM-11:00AM: Abstract Number: 0500

Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention

9:00AM-11:00AM: Abstract Number: 0158

Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes

9:00AM-11:00AM: Abstract Number: 0333

Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life

9:00AM-11:00AM: Abstract Number: 0166

Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States

9:00AM-11:00AM: Abstract Number: 0277

Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0050

Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 0068

Anti-TNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity

9:00AM-11:00AM: Abstract Number: 0603

Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia

9:00AM-11:00AM: Abstract Number: 0706

Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre

9:00AM-11:00AM: Abstract Number: 0638

Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)

9:00AM-11:00AM: Abstract Number: 0463

Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients

9:00AM-11:00AM: Abstract Number: 0491

Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound

9:00AM-11:00AM: Abstract Number: 0151

Arthritis: A Wealth Gap

9:00AM-11:00AM: Abstract Number: 0195

Assessing Cardiovascular Risk in Black and Latino Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0371

Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data

9:00AM-11:00AM: Abstract Number: 0162

Assessing Reproductive Health Counseling and Provider Attitudes in Rheumatology Post Roe v. Wade in Houston, Texas

9:00AM-11:00AM: Abstract Number: 0043

Assessing the Ability of Human Dental Pulp Stem Cells to Modulate the Macrophages Phenotype

9:00AM-11:00AM: Abstract Number: 0342

Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey

9:00AM-11:00AM: Abstract Number: 0326

Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale

9:00AM-11:00AM: Abstract Number: 0509

Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

9:00AM-11:00AM: Abstract Number: 0508

Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

9:00AM-11:00AM: Abstract Number: 0331

Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications

9:00AM-11:00AM: Abstract Number: 0661

Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study

9:00AM-11:00AM: Abstract Number: 0188

Association Between Area Deprivation Index and Organ Damage Accumulation in a Statewide Incident Lupus Cohort

9:00AM-11:00AM: Abstract Number: 0438

Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0416

Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0653

Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0334

Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0414

Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe

9:00AM-11:00AM: Abstract Number: 0130

Association of HLA-DRB1 Alleles with Coronary Artery Calcium, Abdominal Aortic Calcium, and Carotid Intima-media Thickness in a Multi-ethnic Community-living Population

9:00AM-11:00AM: Abstract Number: 0027

Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen

9:00AM-11:00AM: Abstract Number: 0696

Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study

9:00AM-11:00AM: Abstract Number: 0420

Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers

9:00AM-11:00AM: Abstract Number: 0227

Associations of DMARDs with Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases: A Prospective Study

9:00AM-11:00AM: Abstract Number: 0536

Asynchronous Tele Consultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy: Patients Perspective

9:00AM-11:00AM: Abstract Number: 0537

Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation

9:00AM-11:00AM: Abstract Number: 0544

Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0402

Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring

9:00AM-11:00AM: Abstract Number: 0481

Automatically Detect Finger Joint Center and Angle on Hand X-ray: A Deep Learning Model

9:00AM-11:00AM: Abstract Number: 0687

Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain

9:00AM-11:00AM: Abstract Number: 0682

Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients

9:00AM-11:00AM: Abstract Number: 0493

Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque

9:00AM-11:00AM: Abstract Number: 0492

Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?

9:00AM-11:00AM: Abstract Number: 0450

Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting

9:00AM-11:00AM: Abstract Number: 0183

Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)

9:00AM-11:00AM: Abstract Number: 0172

Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0358

Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort

9:00AM-11:00AM: Abstract Number: 0594

Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease

9:00AM-11:00AM: Abstract Number: 0440

Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0692

Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

9:00AM-11:00AM: Abstract Number: 0678

Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 0525

Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0526

Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0523

Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0527

Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0510

Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0421

Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study

9:00AM-11:00AM: Abstract Number: 0457

Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival

9:00AM-11:00AM: Abstract Number: 0391

Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0498

Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)

9:00AM-11:00AM: Abstract Number: 0570

BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations

9:00AM-11:00AM: Abstract Number: PP04

Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0225

Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study

9:00AM-11:00AM: Abstract Number: 0462

Breastfeeding Intention in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 0504

Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

9:00AM-11:00AM: Abstract Number: 0308

Burden of Osteoarthritis Attributable to High BMI in 38 OECD Countries: A Benchmarking Analysis

9:00AM-11:00AM: Abstract Number: 0135

Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0143

Cancer Incidence in Familial Mediterranean Fever

9:00AM-11:00AM: Abstract Number: 0607

CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained

9:00AM-11:00AM: Abstract Number: 0448

Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study

9:00AM-11:00AM: Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 0467

Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 0051

CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis

9:00AM-11:00AM: Abstract Number: 0004

CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation

9:00AM-11:00AM: Abstract Number: 0079

CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles

9:00AM-11:00AM: Abstract Number: 0099

Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0435

Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data

9:00AM-11:00AM: Abstract Number: 0205

Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy

9:00AM-11:00AM: Abstract Number: 0662

Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis

9:00AM-11:00AM: Abstract Number: 0293

Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia

9:00AM-11:00AM: Abstract Number: 0297

Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series

9:00AM-11:00AM: Abstract Number: 0378

Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment

9:00AM-11:00AM: Abstract Number: 0105

Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis

9:00AM-11:00AM: Abstract Number: 0566

Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE

9:00AM-11:00AM: Abstract Number: 0721

Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0076

Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them

9:00AM-11:00AM: Abstract Number: 0252

Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort

9:00AM-11:00AM: Abstract Number: 0636

Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing

9:00AM-11:00AM: Abstract Number: 0659

Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0660

Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0077

Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome

9:00AM-11:00AM: Abstract Number: 0078

Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers

9:00AM-11:00AM: Abstract Number: 0046

Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles

9:00AM-11:00AM: Abstract Number: 0072

Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons

9:00AM-11:00AM: Abstract Number: 0556

Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies

9:00AM-11:00AM: Abstract Number: 0185

Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation

9:00AM-11:00AM: Abstract Number: 0718

Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting

9:00AM-11:00AM: Abstract Number: 0712

Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 0548

Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals

9:00AM-11:00AM: Abstract Number: 0635

Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center

9:00AM-11:00AM: Abstract Number: 0704

Clinical Characteristics and Outcomes in Patients Found to Have Clinically Isolated Aortitis After Aortic Aneurysm Repair: A Single-Center Experience

9:00AM-11:00AM: Abstract Number: 0359

Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment

9:00AM-11:00AM: Abstract Number: 0642

Clinical Characteristics of Systemic Sclerosis, Systemic Sclerosis Overlap Syndromes and Systemic Sclerosis-mixed Connective Tissue Disease in an Asia-Pacific Cohort- an APLAR Scleroderma Special Interest Group Study

9:00AM-11:00AM: Abstract Number: 0370

Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0379

Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation

9:00AM-11:00AM: Abstract Number: 0626

Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study

9:00AM-11:00AM: Abstract Number: 0405

Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study

9:00AM-11:00AM: Abstract Number: 0253

Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity

9:00AM-11:00AM: Abstract Number: 0627

Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database

9:00AM-11:00AM: Abstract Number: 0011

Clock Gene Bmal1 Promotes Transcriptional Activity of NF-κB to Regulate Production of Inflammatory Mediators in RA-FLS

9:00AM-11:00AM: Abstract Number: 0104

Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 0720

Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0249

Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey

9:00AM-11:00AM: Abstract Number: 0338

Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey

9:00AM-11:00AM: Abstract Number: 0437

Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0590

Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 0654

Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population

9:00AM-11:00AM: Abstract Number: 0292

Comparison of Cardiovascular Risk of Myositis Patients and the General Population

9:00AM-11:00AM: Abstract Number: 0637

Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort

9:00AM-11:00AM: Abstract Number: 0568

Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls

9:00AM-11:00AM: Abstract Number: 0693

Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus

9:00AM-11:00AM: Abstract Number: 0445

Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study

9:00AM-11:00AM: Abstract Number: 0656

Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression

9:00AM-11:00AM: Abstract Number: 0477

Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC

9:00AM-11:00AM: Abstract Number: 0645

Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality

9:00AM-11:00AM: Abstract Number: 0472

Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use

9:00AM-11:00AM: Abstract Number: 0336

Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists

9:00AM-11:00AM: Abstract Number: 0064

Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

9:00AM-11:00AM: Abstract Number: 0155

Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0177

Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities

9:00AM-11:00AM: Abstract Number: 0412

COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy

9:00AM-11:00AM: Abstract Number: 0612

COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study

9:00AM-11:00AM: Abstract Number: 0144

COVID-19 Infection in People with Immune Mediated Inflammatory Diseases Who Received SARSCo-V2 Vaccines

9:00AM-11:00AM: Abstract Number: 0211

COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0133

COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 0214

COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network

9:00AM-11:00AM: Abstract Number: 0103

Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0039.5

Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases

9:00AM-11:00AM: Abstract Number: PP06

Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management

9:00AM-11:00AM: Abstract Number: 0108

Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database

9:00AM-11:00AM: Abstract Number: 0243

Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center

9:00AM-11:00AM: Abstract Number: 0671

Decreased Odds of Malignancy with Mycophenolate Use in a Single-Center Scleroderma Cohort

9:00AM-11:00AM: Abstract Number: 0125

Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0192

Demographic and Clinical Factors That Contribute to Clinical Study Enrollment in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0611

Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0122

Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program

9:00AM-11:00AM: Abstract Number: 0591

Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain

9:00AM-11:00AM: Abstract Number: 0262

Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients

9:00AM-11:00AM: Abstract Number: 0423

Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0024

Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay

9:00AM-11:00AM: Abstract Number: 0605

Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

9:00AM-11:00AM: Abstract Number: 0261

Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results

9:00AM-11:00AM: Abstract Number: 0596

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks

9:00AM-11:00AM: Abstract Number: 0502

Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0164

Development and Validation of a Virtual Musculoskeletal Examination Method for Disease Activity Assessment in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0197

Development of a Chikungunya Arthritis Disease Activity Score

9:00AM-11:00AM: Abstract Number: 0303

Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells

9:00AM-11:00AM: Abstract Number: 0559

Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0549

Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients

9:00AM-11:00AM: Abstract Number: 0161

Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe

9:00AM-11:00AM: Abstract Number: 0619

Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0265

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

9:00AM-11:00AM: Abstract Number: 0008

Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice

9:00AM-11:00AM: Abstract Number: 0062

Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes

9:00AM-11:00AM: Abstract Number: 0399

Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory

9:00AM-11:00AM: Abstract Number: 0698

Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings

9:00AM-11:00AM: Abstract Number: 0514

Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study

9:00AM-11:00AM: Abstract Number: 0067

Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples

9:00AM-11:00AM: Abstract Number: 0153

Diminished Vibration Perception and Greater Pressure Pain Sensitivity Are Associated with Worse Knee Osteoarthritis Outcomes Across Sex and Race

9:00AM-11:00AM: Abstract Number: 0429

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study

9:00AM-11:00AM: Abstract Number: 0157

Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective

9:00AM-11:00AM: Abstract Number: 0045

Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 0061

Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0377

Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0403

Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0349

Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care

9:00AM-11:00AM: Abstract Number: 0381

Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data

9:00AM-11:00AM: Abstract Number: 0273

Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement

9:00AM-11:00AM: Abstract Number: 0276

Disease Control in Patients with Monogenetic Autoinflammatory Diseases Under Canakinumab Treatment – Comparison of 30 Months Interim Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 0074

Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects

9:00AM-11:00AM: Abstract Number: 0433

DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0282

DNA Methylation Markers in Peripheral Blood as Effective Diagnostic Biomarkers for Adult-onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 0296

Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM)

9:00AM-11:00AM: Abstract Number: 0616

Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0515

Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 0516

Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry

9:00AM-11:00AM: Abstract Number: 0458

Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience

9:00AM-11:00AM: Abstract Number: 0602

Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0499

Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry

9:00AM-11:00AM: Abstract Number: 0266

E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0649

Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?

9:00AM-11:00AM: Abstract Number: 0470

Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 0522

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status

9:00AM-11:00AM: Abstract Number: 0042

Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells

9:00AM-11:00AM: Abstract Number: 0215

Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort

9:00AM-11:00AM: Abstract Number: 0497

Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0531

Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 0434

Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-

9:00AM-11:00AM: Abstract Number: 0688

Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)

9:00AM-11:00AM: Abstract Number: 0244

Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients

9:00AM-11:00AM: Abstract Number: 0685

Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 0674

Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 0372

Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial

9:00AM-11:00AM: Abstract Number: 0597

Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study

9:00AM-11:00AM: Abstract Number: 0608

Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study

9:00AM-11:00AM: Abstract Number: 0524

Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0716

Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution

9:00AM-11:00AM: Abstract Number: 0309

Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study

9:00AM-11:00AM: Abstract Number: 0422

Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0055

Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses

9:00AM-11:00AM: Abstract Number: 0558

Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment

9:00AM-11:00AM: Abstract Number: 0576

Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers

9:00AM-11:00AM: Abstract Number: 0039

Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0126

Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population

9:00AM-11:00AM: Abstract Number: 0365

Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges

9:00AM-11:00AM: Abstract Number: 0652

Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0639

Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes

9:00AM-11:00AM: Abstract Number: 0658

Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0555

Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists

9:00AM-11:00AM: Abstract Number: 0582

Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial

9:00AM-11:00AM: Abstract Number: 0174

Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0084

Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function

9:00AM-11:00AM: Abstract Number: 0003

Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease

9:00AM-11:00AM: Abstract Number: 0199

Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus

9:00AM-11:00AM: Abstract Number: 0479

Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry

9:00AM-11:00AM: Abstract Number: 0270

Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety

9:00AM-11:00AM: Abstract Number: 0083

Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses

9:00AM-11:00AM: Abstract Number: 0140

Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database

9:00AM-11:00AM: Abstract Number: 0156

Factors Associated with Adherence to Cervical Cancer Screening in Ethnically Diverse Women with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0532

Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 0505

Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study

9:00AM-11:00AM: Abstract Number: 0329

Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 0476

Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0512

Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 0488

Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity

9:00AM-11:00AM: Abstract Number: 0320

Feasibility and Acceptability of Geniculate Artery Embolization for the Treatment of Painful Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0132

Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 0231

Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0085

Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis

9:00AM-11:00AM: Abstract Number: PP08

Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist

9:00AM-11:00AM: Abstract Number: 0306

Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0235

Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study

9:00AM-11:00AM: Abstract Number: 0561

Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry

9:00AM-11:00AM: Abstract Number: 0328

From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App

9:00AM-11:00AM: Abstract Number: 0312

Frontal Lobe Activation and Gait Alterations During Single- and Dual-task Walking in People with Knee Osteoarthritis: A Functional Near-infrared Spectroscopy Study

9:00AM-11:00AM: Abstract Number: 0386

Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0170

Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)

9:00AM-11:00AM: Abstract Number: 0560

Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0015

Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease

9:00AM-11:00AM: Abstract Number: 0034

Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank

9:00AM-11:00AM: Abstract Number: 0715

Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment

9:00AM-11:00AM: Abstract Number: 0447

Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER

9:00AM-11:00AM: Abstract Number: 0059

GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice

9:00AM-11:00AM: Abstract Number: 0057

GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis

9:00AM-11:00AM: Abstract Number: 0241

Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial

9:00AM-11:00AM: Abstract Number: 0240

Gout: A Gateway to Chronic Opioid Use?

9:00AM-11:00AM: Abstract Number: 0094

Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium

9:00AM-11:00AM: Abstract Number: 0550

Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0562

HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0167

Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201

9:00AM-11:00AM: Abstract Number: 0200

Herpes Zoster Prevalence in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0311

Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies

9:00AM-11:00AM: Abstract Number: 0385

Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort

9:00AM-11:00AM: Abstract Number: 0382

Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation

9:00AM-11:00AM: Abstract Number: 0216

High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease

9:00AM-11:00AM: Abstract Number: 0121

High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0394

Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study

9:00AM-11:00AM: Abstract Number: 0484

Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0496

Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0111

Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: PP07

How “Coming Out” About My Lupus Diagnosis Allowed Me to Connect With Patients, Get Involved With Research, and Spread Awareness

9:00AM-11:00AM: Abstract Number: 0520

How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?

9:00AM-11:00AM: Abstract Number: 0439

Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)

9:00AM-11:00AM: Abstract Number: 0469

Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network

9:00AM-11:00AM: Abstract Number: 0396

Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study

9:00AM-11:00AM: Abstract Number: 0165

Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty

9:00AM-11:00AM: Abstract Number: 0315

Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy

9:00AM-11:00AM: Abstract Number: 0383

Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach

9:00AM-11:00AM: Abstract Number: 0398

Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0047

Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis

9:00AM-11:00AM: Abstract Number: 0600

Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline

9:00AM-11:00AM: Abstract Number: 0131

Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model

9:00AM-11:00AM: Abstract Number: 0234

Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out

9:00AM-11:00AM: Abstract Number: 0486

Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity

9:00AM-11:00AM: Abstract Number: 0711

IgA Vasculitis in a Diverse Adult Patient Population

9:00AM-11:00AM: Abstract Number: 0713

IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis

9:00AM-11:00AM: Abstract Number: 0087

Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients

9:00AM-11:00AM: Abstract Number: 0012

Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity

9:00AM-11:00AM: Abstract Number: 0280

Immunosuppression in the Treatment of Susac Syndrome: A Retrospective Evaluation of the Largest Cohort of Susac Syndrome

9:00AM-11:00AM: Abstract Number: 0695

Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study

9:00AM-11:00AM: Abstract Number: 0107

Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020

9:00AM-11:00AM: Abstract Number: 0245

Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout

9:00AM-11:00AM: Abstract Number: 0539

Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0182

Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus

9:00AM-11:00AM: Abstract Number: 0337

Impact of Photosensitivity on Quality of Life in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0466

Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study

9:00AM-11:00AM: Abstract Number: 0513

Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort

9:00AM-11:00AM: Abstract Number: 0009

Impact of Psilocybin on Peripheral Cytokine Production

9:00AM-11:00AM: Abstract Number: 0154

Impact of Social Determinants of Health (SDoH) on Survey Response Times Among Lupus Patients

9:00AM-11:00AM: Abstract Number: 0176

Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0587

Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

9:00AM-11:00AM: Abstract Number: 0530

Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial

9:00AM-11:00AM: Abstract Number: 0149

Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study

9:00AM-11:00AM: Abstract Number: 0233

Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout

9:00AM-11:00AM: Abstract Number: 0091

Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity

9:00AM-11:00AM: Abstract Number: 0310

Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System

9:00AM-11:00AM: Abstract Number: 0123

Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity

9:00AM-11:00AM: Abstract Number: 0198

Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership

9:00AM-11:00AM: Abstract Number: 0248

In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout

9:00AM-11:00AM: Abstract Number: 0141

In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 0239

Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database

9:00AM-11:00AM: Abstract Number: 0648

Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 0120

Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 0218

Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0137

Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 0304

Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort

9:00AM-11:00AM: Abstract Number: 0701

Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study

9:00AM-11:00AM: Abstract Number: 0128

Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort

9:00AM-11:00AM: Abstract Number: 0232

Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA

9:00AM-11:00AM: Abstract Number: 0618

Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis

9:00AM-11:00AM: Abstract Number: 0181

Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States

9:00AM-11:00AM: Abstract Number: 0668

Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 0360

Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial

9:00AM-11:00AM: Abstract Number: 0301

Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort

9:00AM-11:00AM: Abstract Number: 0442

Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices

9:00AM-11:00AM: Abstract Number: 0189

Influence of Social Support on Systemic Lupus Erythematosus (SLE) Outcomes in a Health Disparity Population

9:00AM-11:00AM: Abstract Number: 0332

Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0565

Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0116

Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk

9:00AM-11:00AM: Abstract Number: 0041

Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment

9:00AM-11:00AM: Abstract Number: 0628

Interstitial Lung Disease in Very Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0063

Investigating Macrophage Repopulation in the Synovium

9:00AM-11:00AM: Abstract Number: 0675

Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond

9:00AM-11:00AM: Abstract Number: 0604

Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments

9:00AM-11:00AM: Abstract Number: 0281

Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?

9:00AM-11:00AM: Abstract Number: 0345

Jadas10- and cjadas10-based Disease Activity States for Psoriatic Arthritis, Enthesitis-related Arthritis, and Rf+ Polyarthritis

9:00AM-11:00AM: Abstract Number: 0319

Knee Flexion Contracture Was Associated with Articular Cartilage Loss in the Central Region but Cartilage Preservation in the Posterior Region of the Tibia: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 0471

Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases

9:00AM-11:00AM: Abstract Number: 0460

Knowledge Related to Fertility and Infertility Treatments Among Women with Systemic Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0095

Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE

9:00AM-11:00AM: Abstract Number: 0314

Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 0702

Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study

9:00AM-11:00AM: Abstract Number: 0388

Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0147

Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study

9:00AM-11:00AM: Abstract Number: 0494

Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque

9:00AM-11:00AM: Abstract Number: 0196

Limited Regulatory T Cell Response in Post-Chikungunya Viral Arthritis: A Therapeutic Opportunity?

9:00AM-11:00AM: Abstract Number: 0598

Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

9:00AM-11:00AM: Abstract Number: 0152

Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations

9:00AM-11:00AM: Abstract Number: 0588

Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

9:00AM-11:00AM: Abstract Number: 0355

Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0451

Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis

9:00AM-11:00AM: Abstract Number: 0317

Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

9:00AM-11:00AM: Abstract Number: 0307

Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0519

Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension

9:00AM-11:00AM: Abstract Number: 0511

Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies

9:00AM-11:00AM: Abstract Number: 0679

Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)

9:00AM-11:00AM: Abstract Number: 0425

Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0557

Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE

9:00AM-11:00AM: Abstract Number: 0339

Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort

9:00AM-11:00AM: Abstract Number: 0210

Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors

9:00AM-11:00AM: Abstract Number: 0230

Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome

9:00AM-11:00AM: Abstract Number: 0001

Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis

9:00AM-11:00AM: Abstract Number: 0593

Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: PP03

Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime

9:00AM-11:00AM: Abstract Number: 0255

Lymphoid Mass in the Inferior Turbinate with IgG4 Producing Cells: A Nasal Manifestation of IgG4-RD or a Distinct Chronic Inflammatory Disease?

9:00AM-11:00AM: Abstract Number: 0058

Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation

9:00AM-11:00AM: Abstract Number: 0026

Mapping Cellular Landscape of Esophageal Epithelium in Systemic Sclerosis Using Single-cell Transcriptomics

9:00AM-11:00AM: Abstract Number: 0289

Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity

9:00AM-11:00AM: Abstract Number: 0546

Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis

9:00AM-11:00AM: Abstract Number: 0184

Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE

9:00AM-11:00AM: Abstract Number: 0676

Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center

9:00AM-11:00AM: Abstract Number: 0335

Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool

9:00AM-11:00AM: Abstract Number: 0407

Meteorological Conditions Contribute to the Joint Ultrasound Findings in Patients with Rheumatoid Arthritis: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 0254

Microvascular and Cutaneous Assessment in Adult Patients with Hypermobile Ehlers-Danlos Syndrome

9:00AM-11:00AM: Abstract Number: 0717

Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 0066

Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 0427

Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells

9:00AM-11:00AM: Abstract Number: 0112

Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome

9:00AM-11:00AM: Abstract Number: 0551

Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients

9:00AM-11:00AM: Abstract Number: 0048

Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares

9:00AM-11:00AM: Abstract Number: 0609

Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?

9:00AM-11:00AM: Abstract Number: 0119

Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort

9:00AM-11:00AM: Abstract Number: 0092

Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion

9:00AM-11:00AM: Abstract Number: 0501

Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis

9:00AM-11:00AM: Abstract Number: 0640

Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0180

Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review

9:00AM-11:00AM: Abstract Number: 0352

Musculoskeletal Ultrasound Findings in Children with Psoriasis

9:00AM-11:00AM: Abstract Number: PP13

My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me

9:00AM-11:00AM: Abstract Number: 0291

Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics

9:00AM-11:00AM: Abstract Number: 0567

N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0610

Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0623

Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib

9:00AM-11:00AM: Abstract Number: 0300

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls

9:00AM-11:00AM: Abstract Number: 0351

Needs Assessment Survey of Critical Data Element Completion in Telemedicine Visits for Juvenile Idiopathic Arthritis in the Post-Pandemic Period

9:00AM-11:00AM: Abstract Number: 0629

Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0110

Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

9:00AM-11:00AM: Abstract Number: 0037

New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 0142

New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 0708

NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?

9:00AM-11:00AM: Abstract Number: 0053

Nintedanib Downregulates the Profibrotic M2 Phenotype of Macrophages Obtained from Systemic Sclerosis Patients Affected by Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0256

Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study

9:00AM-11:00AM: Abstract Number: 0419

No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors

9:00AM-11:00AM: Abstract Number: 0275

No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 0278

NOD2 Genotyping Landscape in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 0040

Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage

9:00AM-11:00AM: Abstract Number: 0101

Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 0480

Non-random Sampling in Rheumatology Randomized Controlled Trials: Evidence of Concerning Trial Conduct?

9:00AM-11:00AM: Abstract Number: 0392

Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles

9:00AM-11:00AM: Abstract Number: 0406

Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study

9:00AM-11:00AM: Abstract Number: 0397

Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire

9:00AM-11:00AM: Abstract Number: 0005

Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 0694

Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study

9:00AM-11:00AM: Abstract Number: 0354

Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks

9:00AM-11:00AM: Abstract Number: 0669

Optical Coherence Tomography Angiography in Systemic Sclerosis: Correlations with Morphological and Functional Peripheral Microvascular Status

9:00AM-11:00AM: Abstract Number: 0086

Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

9:00AM-11:00AM: Abstract Number: 0237

Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database

9:00AM-11:00AM: Abstract Number: 0441

Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors

9:00AM-11:00AM: Abstract Number: 0624

Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies

9:00AM-11:00AM: Abstract Number: 0449

Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan

9:00AM-11:00AM: Abstract Number: 0506

Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study

9:00AM-11:00AM: Abstract Number: PP02

Patient Centered Care: The Complete Picture

9:00AM-11:00AM: Abstract Number: 0344

Patient Engagement and Adherence to Digital Study Tasks: WEARable Activity Tracker Study Exploring Rheumatoid Arthritis Patients’ Disease Activity Using Patient-Reported Outcome Measures, Clinical Measures, and Biometric Sensor Data (the WEAR Study)

9:00AM-11:00AM: Abstract Number: 0341

Patient Perspectives on the Usability of a Rheumatoid Arthritis Patient-reported Outcomes Electronic Health Record-based Dashboard: A Mixed-Methods Study

9:00AM-11:00AM: Abstract Number: 0285

Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0330

Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement

9:00AM-11:00AM: Abstract Number: 0290

Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 0263

Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 0468

Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes

9:00AM-11:00AM: Abstract Number: 0436

Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound

9:00AM-11:00AM: Abstract Number: 0220

Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death

9:00AM-11:00AM: Abstract Number: 0073

PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities

9:00AM-11:00AM: Abstract Number: 0096

Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories

9:00AM-11:00AM: Abstract Number: 0581

Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 0580

Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0404

Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?

9:00AM-11:00AM: Abstract Number: 0109

Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 0535

Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex

9:00AM-11:00AM: Abstract Number: 0080

Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses

9:00AM-11:00AM: Abstract Number: 0260

Phenotypes of the Patients with More Than One Autoinflammatory Gene Variant: Classified Diseases and Mixed Autoinflammatory Disorders (MAID)

9:00AM-11:00AM: Abstract Number: 0284

Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases

9:00AM-11:00AM: Abstract Number: 0620

Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry

9:00AM-11:00AM: Abstract Number: 0118

Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 0114

Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS

9:00AM-11:00AM: Abstract Number: 0208

Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System

9:00AM-11:00AM: Abstract Number: 0295

Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 0719

Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study

9:00AM-11:00AM: Abstract Number: 0002

Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases

9:00AM-11:00AM: Abstract Number: 0106

Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds

9:00AM-11:00AM: Abstract Number: 0052

Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes

9:00AM-11:00AM: Abstract Number: 0221

Post-COVID-19 Autoimmune Serologies and Immunophenotypes

9:00AM-11:00AM: Abstract Number: 0029

Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts

9:00AM-11:00AM: Abstract Number: 0373

Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study

9:00AM-11:00AM: Abstract Number: PP09

Practicing Mindfulness to Improve Quality of Life

9:00AM-11:00AM: Abstract Number: 0089

Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 0006

Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile

9:00AM-11:00AM: Abstract Number: 0175

Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach

9:00AM-11:00AM: Abstract Number: 0489

Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study

9:00AM-11:00AM: Abstract Number: 0633

Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study

9:00AM-11:00AM: Abstract Number: 0644

Prediction of Stable SSc-ILD Depends on Definition of ILD Progression

9:00AM-11:00AM: Abstract Number: 0222

Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 0098

Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”

9:00AM-11:00AM: Abstract Number: 0432

Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 0482

Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0259

Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares

9:00AM-11:00AM: Abstract Number: 0573

Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0350

Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 0634

Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study

9:00AM-11:00AM: Abstract Number: 0305

Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 0707

Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0138

Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0630

Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry

9:00AM-11:00AM: Abstract Number: 0647

Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters

9:00AM-11:00AM: Abstract Number: 0615

Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0475

Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States

9:00AM-11:00AM: Abstract Number: 0395

Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 0409

Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0495

Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study

9:00AM-11:00AM: Abstract Number: 0356

PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0643

Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression

9:00AM-11:00AM: Abstract Number: 0288

Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)

9:00AM-11:00AM: Abstract Number: 0203

Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization

9:00AM-11:00AM: Abstract Number: 0578

Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0023

Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0075

Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)

9:00AM-11:00AM: Abstract Number: 0393

Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement

9:00AM-11:00AM: Abstract Number: 0617

Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases

9:00AM-11:00AM: Abstract Number: 0613

Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM

9:00AM-11:00AM: Abstract Number: 0032

Quantification of the Escape from X Chromosome Inactivation with the Million Cell-scale Human Blood Single-cell RNA-seq Datasets Reveals Heterogeneity of Escape Across Immune Cells and Escape in the Autoimmune Disease Conditions

9:00AM-11:00AM: Abstract Number: 0664

Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy

9:00AM-11:00AM: Abstract Number: 0081

RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients

9:00AM-11:00AM: Abstract Number: 0054

RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes

9:00AM-11:00AM: Abstract Number: 0190

Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE

9:00AM-11:00AM: Abstract Number: 0646

Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity

9:00AM-11:00AM: Abstract Number: 0490

Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team

9:00AM-11:00AM: Abstract Number: 0452

Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65

9:00AM-11:00AM: Abstract Number: 0428

Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 0424

Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study

9:00AM-11:00AM: Abstract Number: 0681

Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0592

Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 0691

Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions

9:00AM-11:00AM: Abstract Number: 0148

Recreational Activities in Adults with Rheumatoid Arthritis: Relevance, Difficulty, and Associations with Clinical Outcomes

9:00AM-11:00AM: Abstract Number: 0090

Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0545

Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA)

9:00AM-11:00AM: Abstract Number: 0025

Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0286

Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0316

Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0226

Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study

9:00AM-11:00AM: Abstract Number: PP05

Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups

9:00AM-11:00AM: Abstract Number: 0302

Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients

9:00AM-11:00AM: Abstract Number: 0533

Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?

9:00AM-11:00AM: Abstract Number: 0683

Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0595

Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

9:00AM-11:00AM: Abstract Number: 0684

Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0673

Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials

9:00AM-11:00AM: Abstract Number: 0194

Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers

9:00AM-11:00AM: Abstract Number: 0191

Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients

9:00AM-11:00AM: Abstract Number: 0401

Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index

9:00AM-11:00AM: Abstract Number: 0186

Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure

9:00AM-11:00AM: Abstract Number: 0173

Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0446

Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic

9:00AM-11:00AM: Abstract Number: 0454

Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices

9:00AM-11:00AM: Abstract Number: 0340

Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 0129

Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)

9:00AM-11:00AM: Abstract Number: 0224

Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study

9:00AM-11:00AM: Abstract Number: 0680

Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study

9:00AM-11:00AM: Abstract Number: 0564

Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development

9:00AM-11:00AM: Abstract Number: 0272

Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study

9:00AM-11:00AM: Abstract Number: 0115

Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 0528

Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 0606

Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0206

Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0247

Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States

9:00AM-11:00AM: Abstract Number: 0453

Risk of Lung Cancer in Veterans with Rheumatoid Arthritis in Relation to Use of Conventional versus Biologic or Targeted Synthetic DMARDs

9:00AM-11:00AM: Abstract Number: 0672

Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 0204

Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 0207

Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 0016

Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts

9:00AM-11:00AM: Abstract Number: 0455

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial

9:00AM-11:00AM: Abstract Number: 0246

Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0686

Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 0268

Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 0219

Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab

9:00AM-11:00AM: Abstract Number: 0217

Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study

9:00AM-11:00AM: Abstract Number: 0209

Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 0361

Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience

9:00AM-11:00AM: Abstract Number: 0631

Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review

9:00AM-11:00AM: Abstract Number: 0444

Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: PP10

Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue

9:00AM-11:00AM: Abstract Number: 0621

Scleroderma Renal Crisis: A Large Single-center Experience

9:00AM-11:00AM: Abstract Number: 0601

Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue

9:00AM-11:00AM: Abstract Number: 0461

Self-esteem as a Determinant of Sexual Function in SLE Patients

9:00AM-11:00AM: Abstract Number: 0327

Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre

9:00AM-11:00AM: Abstract Number: 0150

Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 0614

Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0431

Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment

9:00AM-11:00AM: Abstract Number: 0543

Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015

9:00AM-11:00AM: Abstract Number: 0415

Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort

9:00AM-11:00AM: Abstract Number: 0060

Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity

9:00AM-11:00AM: Abstract Number: 0553

Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure

9:00AM-11:00AM: Abstract Number: 0113

Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 0569

Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0572

Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0223

Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0485

Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 0071

Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 0364

Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0529

Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)

9:00AM-11:00AM: Abstract Number: 0145

Sexual Health and Function Screening in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0146

Sexual Health and Self-Perception in Rheumatologic Patients: Has Your Rheumatologist Ever Talked to You About Sexual Health?

9:00AM-11:00AM: Abstract Number: 0021

Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies

9:00AM-11:00AM: Abstract Number: 0093

Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 0714

Single Center Experience of Rituximab Treatment for IgG4-RD Disease in a Large Multi-ethnic Cohort

9:00AM-11:00AM: Abstract Number: 0343

Sjögren’s Disease Patient Experiences with Dry Mouth and Content Validity of the Xerostomia Inventory

9:00AM-11:00AM: Abstract Number: PP12

Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom

9:00AM-11:00AM: Abstract Number: 0088

SLAMF4 Orchestrates the Pathological Cytotoxic Response of CD4+ T Cells in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0705

Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)

9:00AM-11:00AM: Abstract Number: 0179

Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes

9:00AM-11:00AM: Abstract Number: 0193

Social Vulnerability Associations with Mortality in a Lupus Cohort

9:00AM-11:00AM: Abstract Number: 0251

Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0049

Soluble Uric Acid Is an Endogenous Inhibitor of CD38

9:00AM-11:00AM: Abstract Number: 0038

Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis

9:00AM-11:00AM: Abstract Number: 0503

Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging

9:00AM-11:00AM: Abstract Number: 0160

Spine and Sacroiliac Joints Findings in Young Males and Females with Chronic Back Pain Undergoing Magnetic Resonance Imaging in Clinical Practice

9:00AM-11:00AM: Abstract Number: 0390

Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0134

Stressful Life Events in the Year Prior to Their Diagnosis Are Associated with Adult and Pediatric Systemic Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0579

Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes

9:00AM-11:00AM: Abstract Number: 0271

Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients

9:00AM-11:00AM: Abstract Number: 0368

Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients

9:00AM-11:00AM: Abstract Number: 0709

Survival of Adults with IgA Vasculitis

9:00AM-11:00AM: Abstract Number: 0376

Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0418

Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0139

Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry

9:00AM-11:00AM: Abstract Number: 0699

T Cell Subset Analysis in Patients with Large-Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 0534

Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State

9:00AM-11:00AM: Abstract Number: 0599

Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes

9:00AM-11:00AM: Abstract Number: 0584

Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator

9:00AM-11:00AM: Abstract Number: 0384

Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR

9:00AM-11:00AM: Abstract Number: 0007

Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target

9:00AM-11:00AM: Abstract Number: 0456

The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course

9:00AM-11:00AM: Abstract Number: 0014

The 330 Genetic Risk Loci of Systemic Lupus Erythematosus (SLE) Now Known Are Consonant with Multiple Causal Mechanisms Involving Epstein-Barr Virus (EBV)-Encoded Transcription Co-factors (TFs) in EBV-Infected B Cells

9:00AM-11:00AM: Abstract Number: 0056

The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0387

The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0318

The Association of CT-Detected Intra-Articular Mineralization with MRI-Detected Effusion-Synovitis and Hoffa’s Synovitis in Knee OA: The Multicenter Osteoarthritis Study

9:00AM-11:00AM: Abstract Number: 0710

The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review

9:00AM-11:00AM: Abstract Number: 0538

The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort

9:00AM-11:00AM: Abstract Number: 0426

The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0100

The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients

9:00AM-11:00AM: Abstract Number: 0622

The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model

9:00AM-11:00AM: Abstract Number: 0465

The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists

9:00AM-11:00AM: Abstract Number: 0641

The Evaluation of Lower Extremities Arterial Disease in Systemic Sclerosis Patients Through Rheumatologist-Vascular Surgeon Multidisciplinary Management: Preliminary Data from an Italian Single Center Study

9:00AM-11:00AM: Abstract Number: 0552

The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0540

The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study

9:00AM-11:00AM: Abstract Number: 0212

The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE

9:00AM-11:00AM: Abstract Number: 0585

The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 0411

The Impact of Patient-reported Outcomes on Boolean 2.0 Remission Criteria in Rheumatoid Arthritis Patients in Real Clinical Practice -a Multicenter Observational Study: T-FLAG Study-

9:00AM-11:00AM: Abstract Number: 0020

The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups

9:00AM-11:00AM: Abstract Number: 0483

The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)

9:00AM-11:00AM: Abstract Number: 0313

The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0478

The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children

9:00AM-11:00AM: Abstract Number: 0473

The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing

9:00AM-11:00AM: Abstract Number: 0117

The Patient Journey to a First Diagnosis of Systemic Sclerosis: Temporal Disease Pattern Identification Using Machine Learning and Data Mining Among US and Japanese Patients

9:00AM-11:00AM: Abstract Number: 0443

The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis

9:00AM-11:00AM: Abstract Number: 0136

The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use

9:00AM-11:00AM: Abstract Number: 0575

The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice

9:00AM-11:00AM: Abstract Number: 0667

The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 0389

The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms

9:00AM-11:00AM: Abstract Number: 0417

The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0408

The Role of Synovial Biopsy in Evaluating Rheumatoid Arthritis Acitivity in Patients: Findings from a Study of 30 Patients Treated with Adalimumab

9:00AM-11:00AM: Abstract Number: 0102

The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 0507

The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis

9:00AM-11:00AM: Abstract Number: 0348

The Use of Ruxolitinib for Improved Disease Control in Systemic Juvenile Idiopathic Arthritis (sJIA) and Recurrent Macrophage Activation Syndrome (MAS)

9:00AM-11:00AM: Abstract Number: 0657

The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0586

Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort

9:00AM-11:00AM: Abstract Number: 0279

Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo

9:00AM-11:00AM: Abstract Number: 0583

Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients

9:00AM-11:00AM: Abstract Number: 0400

Thresholds of Presenteeism Measurement Instruments for Unacceptable Work Participation and Future Adverse Work Outcomes in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0127

Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0670

Title: Patient Characteristics and Outcomes of Scleroderma Renal Crisis versus Hypertensive Emergencies: A Nationwide Comparative Study

9:00AM-11:00AM: Abstract Number: 0518

Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 0294

Tofacitinib Treatment in Rheumatoid Arthritis Is Associated with Increased Lower Limb Muscle Volume: The Rheumatoid Arthritis and Muscle (RAMUS) Study

9:00AM-11:00AM: Abstract Number: 0201

Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months

9:00AM-11:00AM: Abstract Number: 0347

Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 0178

Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0369

Trajectory of Progression in Transition Readiness in Adolescents with JIA and jSLE

9:00AM-11:00AM: Abstract Number: 0413

Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0283

Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies

9:00AM-11:00AM: Abstract Number: 0097

Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

9:00AM-11:00AM: Abstract Number: 0541

Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study

9:00AM-11:00AM: Abstract Number: 0690

Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy

9:00AM-11:00AM: Abstract Number: 0375

Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands

9:00AM-11:00AM: Abstract Number: 0236

Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings

9:00AM-11:00AM: Abstract Number: 0299

Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019)

9:00AM-11:00AM: Abstract Number: 0666

Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement

9:00AM-11:00AM: Abstract Number: 0542

Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 0574

Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE

9:00AM-11:00AM: Abstract Number: 0163

Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims

9:00AM-11:00AM: Abstract Number: 0258

Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation

9:00AM-11:00AM: Abstract Number: 0325

Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey

9:00AM-11:00AM: Abstract Number: 0159

Understanding the Economic Impact of Autoimmune Eye Disease in the United States

9:00AM-11:00AM: Abstract Number: 0650

Understanding the Employment Landscape in People with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0459

Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 0563

Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0689

Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2

9:00AM-11:00AM: Abstract Number: 0380

Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi

9:00AM-11:00AM: Abstract Number: 0625

Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0019

Use of High-plex Data Reveals Novel Insights into the Temporal Artery Processus of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 0321

Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0346

Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)

9:00AM-11:00AM: Abstract Number: 0410

Usefulness of RAPID3 in Assessing Unmet Needs of Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity　-a Multicenter Observational Study: T-FLAG Study-

9:00AM-11:00AM: Abstract Number: 0036

Using Genotyping and Chromatin Data in CD4+ T Cells to Nominate Causal Variants on JIA Risk Haplotypes and to Identify Their Target Genes

9:00AM-11:00AM: Abstract Number: 0035

Using Genotyping and Functional Data from Monocytes to Identify Risk-Driving SNPs on JIA Risk Haplotypes

9:00AM-11:00AM: Abstract Number: 0124

Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network

9:00AM-11:00AM: Abstract Number: 0663

Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis

9:00AM-11:00AM: Abstract Number: 0022

Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients

9:00AM-11:00AM: Abstract Number: 0353

Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods

9:00AM-11:00AM: Abstract Number: 0322

Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0250

Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial Fluid

9:00AM-11:00AM: Abstract Number: 0357

Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting

9:00AM-11:00AM: Abstract Number: 0267

Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists

9:00AM-11:00AM: Abstract Number: 0229

Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout

9:00AM-11:00AM: Abstract Number: 0242

Venous Thromboembolism in Patients with Gout in the US

9:00AM-11:00AM: Abstract Number: PP11

We Suffered For Decades, But Then She Was Born

9:00AM-11:00AM: Abstract Number: 0168

What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment

9:00AM-11:00AM: Abstract Number: 0213

When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 0517

Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?

9:00AM-11:00AM: Abstract Number: 0521

Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 0017

Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity

9:00AM-11:00AM: Abstract Number: PP01

You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis

11:00AM-12:30PM: Abstract Number: 0722

Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

11:00AM-12:30PM: Abstract Number: 0726

Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs

11:00AM-12:30PM: Abstract Number: 0723

Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension

11:00AM-12:30PM: Abstract Number: 0725

Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

11:00AM-12:30PM: Abstract Number: 0724

Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model

2:00PM-3:30PM: Abstract Number: 0738

A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 0771

A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 0727

A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine

2:00PM-3:30PM: Abstract Number: 0786

A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort

2:00PM-3:30PM: Abstract Number: 0741

Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors

2:00PM-3:30PM: Abstract Number: 0764

An Atypical ClassRheum: RheumMadness, a Collaborative Rheumatology Competition Building Knowledge and Community

2:00PM-3:30PM: Abstract Number: 0745

Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 0780

Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach

2:00PM-3:30PM: Abstract Number: 0748

Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT

2:00PM-3:30PM: Abstract Number: 0755

Changes in Rheumatology Providers’ Perceptions of Telehealth Appropriateness from 2021 to 2022

2:00PM-3:30PM: Abstract Number: 0777

Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis

2:00PM-3:30PM: Abstract Number: 0758

Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease

2:00PM-3:30PM: Abstract Number: 0747

Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica

2:00PM-3:30PM: Abstract Number: 0782

Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies

2:00PM-3:30PM: Abstract Number: 0767

Current Musculoskeletal Ultrasound Practices of 12 Years of past Participants of a 10-Months Rheumatology Ultrasound Training Program (Ultrasound School of North American Rheumatologists)

2:00PM-3:30PM: Abstract Number: 0736

Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics

2:00PM-3:30PM: Abstract Number: 0774

Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study

2:00PM-3:30PM: Abstract Number: 0735

Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 0759

Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry

2:00PM-3:30PM: Abstract Number: 0769

Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort

2:00PM-3:30PM: Abstract Number: 0775

Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study

2:00PM-3:30PM: Abstract Number: 0776

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study

2:00PM-3:30PM: Abstract Number: 0761

EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD)

2:00PM-3:30PM: Abstract Number: 0791

Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis

2:00PM-3:30PM: Abstract Number: 0753

Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System

2:00PM-3:30PM: Abstract Number: 0733

Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening

2:00PM-3:30PM: Abstract Number: 0757

Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals

2:00PM-3:30PM: Abstract Number: 0734

Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases

2:00PM-3:30PM: Abstract Number: 0749

Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study

2:00PM-3:30PM: Abstract Number: 0779

Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)

2:00PM-3:30PM: Abstract Number: 0784

Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

2:00PM-3:30PM: Abstract Number: 0762

Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction

2:00PM-3:30PM: Abstract Number: 0781

Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials

2:00PM-3:30PM: Abstract Number: 0739

Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 0772

MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease

2:00PM-3:30PM: Abstract Number: 0750

Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation

2:00PM-3:30PM: Abstract Number: 0730

NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 0744

Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 0770

Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes

2:00PM-3:30PM: Abstract Number: 0751

Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023

2:00PM-3:30PM: Abstract Number: 0740

Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease

2:00PM-3:30PM: Abstract Number: 0765

RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives

2:00PM-3:30PM: Abstract Number: 0743

Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

2:00PM-3:30PM: Abstract Number: 0742

Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

2:00PM-3:30PM: Abstract Number: 0729

ROCK1 Orchestrates B-cell Differentiation Under Stress

2:00PM-3:30PM: Abstract Number: 0732

Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?

2:00PM-3:30PM: Abstract Number: 0792

Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease

2:00PM-3:30PM: Abstract Number: 0773

Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity

2:00PM-3:30PM: Abstract Number: 0763

Sticking the Landing: A 3-Year Qualitative Longitudinal Study on Navigating Transitions in Pediatric Rheumatology Fellowship

2:00PM-3:30PM: Abstract Number: 0728

Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype

2:00PM-3:30PM: Abstract Number: 0789

Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis

2:00PM-3:30PM: Abstract Number: 0746

The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 0778

The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial

2:00PM-3:30PM: Abstract Number: 0766

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

2:00PM-3:30PM: Abstract Number: 0785

Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity

2:00PM-3:30PM: Abstract Number: 0783

Tolerability of CAR T Cell Therapy in Autoimmune Disease

2:00PM-3:30PM: Abstract Number: 0754

Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 0790

Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD)

2:00PM-3:30PM: Abstract Number: 0760

Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study

2:00PM-3:30PM: Abstract Number: 0752

Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators

2:00PM-3:30PM: Abstract Number: 0787

Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry

2:00PM-3:30PM: Abstract Number: 0737

Unraveling Pathophysiology and Hematopoiesis of VEXAS Syndrome by Multi-omics Analysis and Targeted Gene Editing

2:00PM-3:30PM: Abstract Number: 0768

Using Participatory Design-Thinking Process to Create a More Applicant-Centered Rheumatology Fellowship Interview Experience

2:00PM-3:30PM: Abstract Number: 0756

Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative

2:00PM-3:30PM: Abstract Number: 0788

Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis

2:00PM-3:30PM: Abstract Number: 0731

ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0798

A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages

4:00PM-5:30PM: Abstract Number: 0837

A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis

4:00PM-5:30PM: Abstract Number: 0825

A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)

4:00PM-5:30PM: Abstract Number: 0835

Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial

4:00PM-5:30PM: Abstract Number: 0816

Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study

4:00PM-5:30PM: Abstract Number: 0800

CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis

4:00PM-5:30PM: Abstract Number: 0857

Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan

4:00PM-5:30PM: Abstract Number: 0834

Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry

4:00PM-5:30PM: Abstract Number: 0811

Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study

4:00PM-5:30PM: Abstract Number: 0817

Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)

4:00PM-5:30PM: Abstract Number: 0832

Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry

4:00PM-5:30PM: Abstract Number: 0805

De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis

4:00PM-5:30PM: Abstract Number: 0829

Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study

4:00PM-5:30PM: Abstract Number: 0824

Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study

4:00PM-5:30PM: Abstract Number: 0827

Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 0826

Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0847

Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0856

Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study

4:00PM-5:30PM: Abstract Number: 0853

Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System

4:00PM-5:30PM: Abstract Number: 0806

Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial

4:00PM-5:30PM: Abstract Number: 0821

Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study

4:00PM-5:30PM: Abstract Number: 0839

Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study

4:00PM-5:30PM: Abstract Number: 0818

Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial

4:00PM-5:30PM: Abstract Number: 0844

Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort

4:00PM-5:30PM: Abstract Number: 0822

From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes

4:00PM-5:30PM: Abstract Number: 0840

Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study

4:00PM-5:30PM: Abstract Number: 0799

Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0803

IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome

4:00PM-5:30PM: Abstract Number: 0807

Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records

4:00PM-5:30PM: Abstract Number: 0838

Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections

4:00PM-5:30PM: Abstract Number: 0797

Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis

4:00PM-5:30PM: Abstract Number: 0815

Intermittent Fasting Reduces Crystal-induced Inflammation

4:00PM-5:30PM: Abstract Number: 0828

Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire

4:00PM-5:30PM: Abstract Number: 0812

Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process

4:00PM-5:30PM: Abstract Number: 0801

LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease

4:00PM-5:30PM: Abstract Number: 0854

Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis

4:00PM-5:30PM: Abstract Number: 0842

Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort

4:00PM-5:30PM: Abstract Number: 0851

Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms

4:00PM-5:30PM: Abstract Number: 0833

Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort

4:00PM-5:30PM: Abstract Number: 0794

Microbiota-dependent Indole Production Is Required for the Development of Collagen-induced Arthritis

4:00PM-5:30PM: Abstract Number: 0849

Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 0804

Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice

4:00PM-5:00PM: Abstract Number: PP16

Peer Health Coaches Help Scleroderma Patients Cope with Isolation

4:00PM-5:30PM: Abstract Number: 0848

Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients

4:00PM-5:30PM: Abstract Number: 0850

Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis

4:00PM-5:30PM: Abstract Number: 0843

Predictive Validity of Data-driven Definitions for Active and Structural Lesions in the SI Joints Typical for Axial SpA: A 2-year Follow-up in the SPondyloArthritis Caught Early Cohort

4:00PM-5:30PM: Abstract Number: 0846

Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB – GRB2/ERK/RUNX2 Pathway

4:00PM-5:00PM: Abstract Number: PP14

Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease

4:00PM-5:30PM: Abstract Number: 0820

Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results

4:00PM-5:30PM: Abstract Number: 0858

Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis

4:00PM-5:30PM: Abstract Number: 0808

Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System

4:00PM-5:30PM: Abstract Number: 0855

Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis

4:00PM-5:30PM: Abstract Number: 0819

Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis

4:00PM-5:30PM: Abstract Number: 0796

Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis

4:00PM-5:30PM: Abstract Number: 0852

Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay

4:00PM-5:30PM: Abstract Number: 0823

Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort

4:00PM-5:30PM: Abstract Number: 0813

Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants

4:00PM-5:30PM: Abstract Number: 0841

Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis

4:00PM-5:30PM: Abstract Number: 0802

Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

4:00PM-5:30PM: Abstract Number: 0810

Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic

4:00PM-5:30PM: Abstract Number: 0793

The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production

4:00PM-5:30PM: Abstract Number: 0795

The Focal Adhesion Protein Lasp1 Links the Arp2/3 Complex to Cell-to-cell Contact Formation in Arthritic Fibroblast-like Synoviocytes

4:00PM-5:30PM: Abstract Number: 0830

The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis

4:00PM-5:30PM: Abstract Number: 0845

The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort

4:00PM-5:00PM: Abstract Number: PP15

Toward a Frontier Beyond the Barriers of Position and Prejudice

4:00PM-5:30PM: Abstract Number: 0814

Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial

4:00PM-5:30PM: Abstract Number: 0831

Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study

4:00PM-5:30PM: Abstract Number: 0809

Underserved by Rehabilitation: Characteristics Among Adults with Rheumatoid Arthritis

4:00PM-5:00PM: Abstract Number: PP17

Utilizing Support Networks to Improve Patient Outcomes

4:00PM-5:30PM: Abstract Number: 0836

Vagotomy and Subsequent Risk of Rheumatoid Arthritis and Osteoarthritis: A Danish Register-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1216

“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1094

“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1032

“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)

9:00AM-11:00AM: Abstract Number: 1262

“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches

9:00AM-11:00AM: Abstract Number: 1258

“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0910

17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice

9:00AM-11:00AM: Abstract Number: 1148

A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 1150

A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era

9:00AM-11:00AM: Abstract Number: 1471

A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1100

A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule

9:00AM-11:00AM: Abstract Number: 1067

A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0927

A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus

9:00AM-11:00AM: Abstract Number: 1398

A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1124

A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China

9:00AM-11:00AM: Abstract Number: 1003

A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis

9:00AM-11:00AM: Abstract Number: 0866

A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies

9:00AM-11:00AM: Abstract Number: 0940

A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome

9:00AM-11:00AM: Abstract Number: 1083

A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative

9:00AM-11:00AM: Abstract Number: 1191

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee

9:00AM-11:00AM: Abstract Number: 1430

A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1096

A Quality Improvement Project About Medication Adherence to Understand What Questions Rheumatology Patients Have About Their Medications, and How They Answer Them

9:00AM-11:00AM: Abstract Number: 1142

A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1531

A Retrospective Analysis of the Efficacy of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): A TriNetX Database Study

9:00AM-11:00AM: Abstract Number: 1125

A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain

9:00AM-11:00AM: Abstract Number: 1011

A Rheumatology Model of Care Re-design: Integrating the Advanced Practice Provider

9:00AM-11:00AM: Abstract Number: 1366

A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 1184

A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker

9:00AM-11:00AM: Abstract Number: 1318

Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial

9:00AM-11:00AM: Abstract Number: 1556

Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 1129

Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study

9:00AM-11:00AM: Abstract Number: 1400

Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1458

Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity

9:00AM-11:00AM: Abstract Number: 0882

Activation of Ovarian Cancer G-Protein Coupled Receptor (OGR1) Attenuates Chondrocytes Inflammation via ERK1/2 Signaling Pathways in an in Vitro Model of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1292

Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD

9:00AM-11:00AM: Abstract Number: 1527

Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 1336

Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering

9:00AM-11:00AM: Abstract Number: 1010

Advanced Clinician Practitioners in Arthritis Care: A Workforce Profile

9:00AM-11:00AM: Abstract Number: 1241

Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort

9:00AM-11:00AM: Abstract Number: 1395

Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1242

Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1169

All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China

9:00AM-11:00AM: Abstract Number: 1020

An Increase in Safety Outcome Trials and the Issue of Informed Consent

9:00AM-11:00AM: Abstract Number: 1409

Analysis of Soluble Biomarkers in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1577

Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome

9:00AM-11:00AM: Abstract Number: 1534

ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region

9:00AM-11:00AM: Abstract Number: 1077

Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab

9:00AM-11:00AM: Abstract Number: 0934

Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1177

Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients

9:00AM-11:00AM: Abstract Number: 1174

Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review

9:00AM-11:00AM: Abstract Number: 1163

Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort

9:00AM-11:00AM: Abstract Number: 0963

Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1160

Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1467

Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1062

Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity

9:00AM-11:00AM: Abstract Number: 1235

Apparent Diffusion Coefficient (ADC) from Diffusion Weighted Imaging (DWI) as an Objective Tool to Differentiate Normal Maturational Subchondral Signal from Inflammation at the Sacroiliac Joint in Youth

9:00AM-11:00AM: Abstract Number: 1576

Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria

9:00AM-11:00AM: Abstract Number: 1112

AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses

9:00AM-11:00AM: Abstract Number: 1371

Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study

9:00AM-11:00AM: Abstract Number: 1210

Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0985

Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry

9:00AM-11:00AM: Abstract Number: 1246

Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis

9:00AM-11:00AM: Abstract Number: 1567

Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 1065

Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 0983

Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study

9:00AM-11:00AM: Abstract Number: 0992

Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray

9:00AM-11:00AM: Abstract Number: 1137

Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0908

Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function

9:00AM-11:00AM: Abstract Number: 1199

Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan

9:00AM-11:00AM: Abstract Number: 1448

Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1488

Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1019

Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions

9:00AM-11:00AM: Abstract Number: 0975

Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population

9:00AM-11:00AM: Abstract Number: 1196

Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies

9:00AM-11:00AM: Abstract Number: 1359

Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1461

Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL

9:00AM-11:00AM: Abstract Number: 0990

Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry

9:00AM-11:00AM: Abstract Number: 1474

Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)

9:00AM-11:00AM: Abstract Number: 1283

Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness

9:00AM-11:00AM: Abstract Number: 0943

Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner

9:00AM-11:00AM: Abstract Number: 1192

Autoimmune Thyroid Disease Associates with Symptomatic Hand Osteoarthritis in Older Persons in the Third National Health and Nutrition Examination Survey

9:00AM-11:00AM: Abstract Number: 1555

Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 0889

Axl Receptor Tyrosine Kinase Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization

9:00AM-11:00AM: Abstract Number: 1511

B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1042

B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis

9:00AM-11:00AM: Abstract Number: 0998

Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives

9:00AM-11:00AM: Abstract Number: 1028

Barriers to Total Joint Arthroplasty for Patients Residing in High-Poverty Communities

9:00AM-11:00AM: Abstract Number: 1074

Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1284

Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study

9:00AM-11:00AM: Abstract Number: 1565

Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months

9:00AM-11:00AM: Abstract Number: 1562

Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population

9:00AM-11:00AM: Abstract Number: 1439

Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA

9:00AM-11:00AM: Abstract Number: 1198

Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1433

Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1437

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study

9:00AM-11:00AM: Abstract Number: 1441

Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial

9:00AM-11:00AM: Abstract Number: 1415

Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1066

Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples

9:00AM-11:00AM: Abstract Number: 1302

Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study

9:00AM-11:00AM: Abstract Number: 1147

Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

9:00AM-11:00AM: Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1300

Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression

9:00AM-11:00AM: Abstract Number: 1364

Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1176

Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1509

Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1164

Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study

9:00AM-11:00AM: Abstract Number: 1055

Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort

9:00AM-11:00AM: Abstract Number: 1171

Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1343

Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years

9:00AM-11:00AM: Abstract Number: 1462

Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

9:00AM-11:00AM: Abstract Number: 1207

Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database

9:00AM-11:00AM: Abstract Number: 1121

Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 0880

CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA

9:00AM-11:00AM: Abstract Number: 1553

Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1308

Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study

9:00AM-11:00AM: Abstract Number: 1330

Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

9:00AM-11:00AM: Abstract Number: 1136

Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations

9:00AM-11:00AM: Abstract Number: 1482

Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan

9:00AM-11:00AM: Abstract Number: 1420

Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1265

Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?

9:00AM-11:00AM: Abstract Number: 1504

Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S

9:00AM-11:00AM: Abstract Number: 1023

Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes

9:00AM-11:00AM: Abstract Number: 1377

Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study

9:00AM-11:00AM: Abstract Number: 1087

Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach

9:00AM-11:00AM: Abstract Number: 1244

Characterizing Lupus in African American Children in Southern United States

9:00AM-11:00AM: Abstract Number: 1525

Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1477

Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1255

Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1268

Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup

9:00AM-11:00AM: Abstract Number: 1081

Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial

9:00AM-11:00AM: Abstract Number: 1561

Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study

9:00AM-11:00AM: Abstract Number: 0869

Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1239

Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort

9:00AM-11:00AM: Abstract Number: 1450

Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico

9:00AM-11:00AM: Abstract Number: 1486

Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)

9:00AM-11:00AM: Abstract Number: 1131

Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort

9:00AM-11:00AM: Abstract Number: 1154

Clinical Presentation of IgG4-Related Disease. Single Referral Hospital Experience and Literature Review

9:00AM-11:00AM: Abstract Number: 1496

Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1234

Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity

9:00AM-11:00AM: Abstract Number: 1183

CoLchicine for Treatment of OsteoArthritis of the Knee—Updated Data from a Double-blind, Placebo-controlled Trial

9:00AM-11:00AM: Abstract Number: 1564

Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease

9:00AM-11:00AM: Abstract Number: 1394

Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study

9:00AM-11:00AM: Abstract Number: 1113

Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients

9:00AM-11:00AM: Abstract Number: 1517

Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 0965

Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1334

Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

9:00AM-11:00AM: Abstract Number: 1568

Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 1043

Comparison of Optical and Ultrasound Imaging in Lupus Arthritis

9:00AM-11:00AM: Abstract Number: 0970

Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change

9:00AM-11:00AM: Abstract Number: 1559

Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

9:00AM-11:00AM: Abstract Number: 1310

Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice

9:00AM-11:00AM: Abstract Number: 0900

Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro

9:00AM-11:00AM: Abstract Number: 0899

Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy

9:00AM-11:00AM: Abstract Number: 1396

Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses

9:00AM-11:00AM: Abstract Number: 1347

Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination

9:00AM-11:00AM: Abstract Number: 1016

Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1141

COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1297

COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 1017

Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes

9:00AM-11:00AM: Abstract Number: 1249

Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1039

Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study

9:00AM-11:00AM: Abstract Number: 1500

Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies

9:00AM-11:00AM: Abstract Number: 1170

Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life

9:00AM-11:00AM: Abstract Number: 0887

Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells

9:00AM-11:00AM: Abstract Number: 1557

De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

9:00AM-11:00AM: Abstract Number: 1296

Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 0938

Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum

9:00AM-11:00AM: Abstract Number: 1560

Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China

9:00AM-11:00AM: Abstract Number: 1495

Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells

9:00AM-11:00AM: Abstract Number: 0881

Deficiency of the Pattern-recognition Receptor CD14 Protects Against LPS-induced Inhibition of Osteoclastogenesis in Vitro

9:00AM-11:00AM: Abstract Number: 1407

Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA

9:00AM-11:00AM: Abstract Number: 1355

Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices

9:00AM-11:00AM: Abstract Number: 1373

Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1480

Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region

9:00AM-11:00AM: Abstract Number: 1263

Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1158

Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection

9:00AM-11:00AM: Abstract Number: 1211

Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population

9:00AM-11:00AM: Abstract Number: 1144

Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years

9:00AM-11:00AM: Abstract Number: 1290

Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1188

Development of a Method to Isolate Functional Mitochondria and Assess Their Functionality and Integration in Joint Tissues: In Vitro and in Vivo Models

9:00AM-11:00AM: Abstract Number: 1093

Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 0949

Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion

9:00AM-11:00AM: Abstract Number: 1558

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

9:00AM-11:00AM: Abstract Number: 1368

Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s

9:00AM-11:00AM: Abstract Number: 1548

Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 1050

Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols

9:00AM-11:00AM: Abstract Number: 1035

Diagnostic and Educational Utility of an Ultrasound Protocol for Evaluation of Hand Pain in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1405

Diagnostic Delay of Axial Spondyloarthritis in African American Patients

9:00AM-11:00AM: Abstract Number: 1230

Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive

9:00AM-11:00AM: Abstract Number: 1539

Digital Ischemia, a Rare Manifestation in Anti-neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)

9:00AM-11:00AM: Abstract Number: 1317

Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1218

Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective

9:00AM-11:00AM: Abstract Number: 1476

Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study

9:00AM-11:00AM: Abstract Number: 1547

Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 1503

Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1001

Distance Not Travelled in a Tele-Rheumatology Shared Care Model: Leveraging the Expertise of an Advanced Clinician Practitioner in Arthritis Care (ACPAC)-trained Extended Role Practitioner (ERP) in Rural-remote Ontario

9:00AM-11:00AM: Abstract Number: 0924

Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE

9:00AM-11:00AM: Abstract Number: 1426

Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib

9:00AM-11:00AM: Abstract Number: 1323

Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1

9:00AM-11:00AM: Abstract Number: 1417

Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1421

Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)

9:00AM-11:00AM: Abstract Number: 1104

Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

9:00AM-11:00AM: Abstract Number: 0931

Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation

9:00AM-11:00AM: Abstract Number: 1037

Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy

9:00AM-11:00AM: Abstract Number: 1490

Early Experience with SGLT2i in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1424

Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients

9:00AM-11:00AM: Abstract Number: 1413

Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST

9:00AM-11:00AM: Abstract Number: 1321

Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1337

Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1361

Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers

9:00AM-11:00AM: Abstract Number: 1335

Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA)

9:00AM-11:00AM: Abstract Number: 1414

Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0956

Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0903

Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 1327

Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials

9:00AM-11:00AM: Abstract Number: 1105

Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients

9:00AM-11:00AM: Abstract Number: 1197

Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial

9:00AM-11:00AM: Abstract Number: 1344

Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1518

Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1569

Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study

9:00AM-11:00AM: Abstract Number: 1425

Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 1041

Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging

9:00AM-11:00AM: Abstract Number: 1510

Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC)

9:00AM-11:00AM: Abstract Number: 1438

Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA

9:00AM-11:00AM: Abstract Number: 1215

Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

9:00AM-11:00AM: Abstract Number: 1418

Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 1382

Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1427

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials

9:00AM-11:00AM: Abstract Number: 1322

Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models

9:00AM-11:00AM: Abstract Number: 0988

Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)

9:00AM-11:00AM: Abstract Number: 1315

Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies

9:00AM-11:00AM: Abstract Number: 1497

Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications

9:00AM-11:00AM: Abstract Number: 1025

Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients

9:00AM-11:00AM: Abstract Number: 1095

Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures

9:00AM-11:00AM: Abstract Number: 1049

Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA)

9:00AM-11:00AM: Abstract Number: 0868

Enhancing Oxidative Phosphorylation Through PDK2 Depletion Alleviates Cartilage Degradation in Surgically Induced Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1546

Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

9:00AM-11:00AM: Abstract Number: 1552

Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France

9:00AM-11:00AM: Abstract Number: 1535

Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 0907

Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1115

EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1245

Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 1189

Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1168

Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD)

9:00AM-11:00AM: Abstract Number: 1451

Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience

9:00AM-11:00AM: Abstract Number: 1320

Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept

9:00AM-11:00AM: Abstract Number: 1103

Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy

9:00AM-11:00AM: Abstract Number: 1449

Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1540

Evaluation of the Validity of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Antineutrophil Cytoplasmic Antibody-associated Vasculitis for an Asian Population on the Basis of the Patterns of Organ Involvement

9:00AM-11:00AM: Abstract Number: 1526

Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 1226

Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1402

Exceeding Activity Targets but Missing the Mark with Sleep: Mapping 24-Hour Movement Guidelines in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1159

Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients

9:00AM-11:00AM: Abstract Number: 1157

Experience of Pain in Adults with Idiopathic Inflammatory Myopathies, Myositis

9:00AM-11:00AM: Abstract Number: 1358

Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1432

Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions

9:00AM-11:00AM: Abstract Number: 1133

Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

9:00AM-11:00AM: Abstract Number: 1069

Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS)

9:00AM-11:00AM: Abstract Number: 1566

Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1194

Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain

9:00AM-11:00AM: Abstract Number: 1223

Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis

9:00AM-11:00AM: Abstract Number: 1365

Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study

9:00AM-11:00AM: Abstract Number: 1404

Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 0984

Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients

9:00AM-11:00AM: Abstract Number: 1360

Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort

9:00AM-11:00AM: Abstract Number: 1127

Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1221

Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1381

Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 0947

Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1102

Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)

9:00AM-11:00AM: Abstract Number: 1498

First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0953

Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0873

FOXO Activators as Drugs for Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1201

Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1288

Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1139

From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic

9:00AM-11:00AM: Abstract Number: 1393

Fully Automated Detection of Active Sacroiliitis in Patients with Axial Spondyloarthritis: A Machine Learning-Based Analysis Magnetic Resonance Image

9:00AM-11:00AM: Abstract Number: 1384

Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0888

Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model

9:00AM-11:00AM: Abstract Number: 0942

G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling

9:00AM-11:00AM: Abstract Number: 1146

Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases

9:00AM-11:00AM: Abstract Number: 0930

Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage

9:00AM-11:00AM: Abstract Number: 1109

Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

9:00AM-11:00AM: Abstract Number: 1031

Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System

9:00AM-11:00AM: Abstract Number: 1446

Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database

9:00AM-11:00AM: Abstract Number: 1202

Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals

9:00AM-11:00AM: Abstract Number: 0955

GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis

9:00AM-11:00AM: Abstract Number: 1428

Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)

9:00AM-11:00AM: Abstract Number: 1295

Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort

9:00AM-11:00AM: Abstract Number: 1015

Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives

9:00AM-11:00AM: Abstract Number: 1483

High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study

9:00AM-11:00AM: Abstract Number: 1351

HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center

9:00AM-11:00AM: Abstract Number: 0939

HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1145

Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat

9:00AM-11:00AM: Abstract Number: 0884

Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1350

Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record

9:00AM-11:00AM: Abstract Number: 1126

Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1079

Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements

9:00AM-11:00AM: Abstract Number: 0923

Identification of Lupus Nephritis Kidney Immune Populations via Hi-Resolution 20-Plex Immunohistochemistry Single-Cell Spatial Analyses

9:00AM-11:00AM: Abstract Number: 1059

Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data

9:00AM-11:00AM: Abstract Number: 1155

Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis

9:00AM-11:00AM: Abstract Number: 1270

Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1084

Identifying and Addressing Disparities in Health Literacy in Patients with Rheumatic Diseases Through Point of Care Distribution of Patient Education Materials

9:00AM-11:00AM: Abstract Number: 1520

Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method

9:00AM-11:00AM: Abstract Number: 1444

Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study

9:00AM-11:00AM: Abstract Number: 0978

Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model

9:00AM-11:00AM: Abstract Number: 1008

Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use

9:00AM-11:00AM: Abstract Number: 0915

IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach

9:00AM-11:00AM: Abstract Number: 0925

IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus

9:00AM-11:00AM: Abstract Number: 0937

IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice

9:00AM-11:00AM: Abstract Number: 1054

Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT

9:00AM-11:00AM: Abstract Number: 1056

Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study

9:00AM-11:00AM: Abstract Number: 0946

Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts

9:00AM-11:00AM: Abstract Number: 1272

Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study

9:00AM-11:00AM: Abstract Number: 1063

Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 1578

Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1287

Impact of Body Mass Index (BMI) on Rheumatoid Arthritis Disease Activity and Musculoskeletal Ultrasound Measures

9:00AM-11:00AM: Abstract Number: 1286

Impact of Body Mass Index (BMI) on Upper versus Lower Extremity Joints Assessed Using Clinical and Musculoskeletal Ultrasound Measures in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1466

Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020

9:00AM-11:00AM: Abstract Number: 1307

Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER

9:00AM-11:00AM: Abstract Number: 0997

Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1408

Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort

9:00AM-11:00AM: Abstract Number: 1075

Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)

9:00AM-11:00AM: Abstract Number: 1460

Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1419

Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab

9:00AM-11:00AM: Abstract Number: 1060

Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1040

Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT

9:00AM-11:00AM: Abstract Number: 1341

Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores

9:00AM-11:00AM: Abstract Number: 1423

Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial

9:00AM-11:00AM: Abstract Number: 0936

Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis

9:00AM-11:00AM: Abstract Number: 1013

Implementation of a Rheumatology-Based Social Determinants of Health Screening Program to Uncover and Address Needs in a Multihospital Health Care System

9:00AM-11:00AM: Abstract Number: 1550

Importance of Shared Decision-Making for Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1038

Improved Assessment of Structural Damage in the Spine in Patients with Axial Spondyloarthritis by MRI-based Synthetic CT: A Comparison with Low-dose CT and X-ray

9:00AM-11:00AM: Abstract Number: 1090

Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center

9:00AM-11:00AM: Abstract Number: 1232

Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 1416

Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1412

Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

9:00AM-11:00AM: Abstract Number: 1099

Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder

9:00AM-11:00AM: Abstract Number: 1088

Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1098

Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1089

Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1362

Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs

9:00AM-11:00AM: Abstract Number: 1092

Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 1392

Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project

9:00AM-11:00AM: Abstract Number: 1097

Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program

9:00AM-11:00AM: Abstract Number: 0912

Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1442

Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1175

Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1000

Incorporation of Social Drivers of Health Screening into a Structured Healthcare Transition Program for Adolescents and Young Adults with Chronic Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1072

Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1086

Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution

9:00AM-11:00AM: Abstract Number: 0972

Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population

9:00AM-11:00AM: Abstract Number: 1447

Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis

9:00AM-11:00AM: Abstract Number: 1544

Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis

9:00AM-11:00AM: Abstract Number: 1289

Increases in Serum Levels of Tartrate-Resistant Acid Phosphatase 5b Reflected Radiographic Progression of Joint Damage in Treated Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1140

Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist

9:00AM-11:00AM: Abstract Number: 1452

Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1316

Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1047

Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints

9:00AM-11:00AM: Abstract Number: 1573

Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020

9:00AM-11:00AM: Abstract Number: 1325

Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years

9:00AM-11:00AM: Abstract Number: 1130

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI

9:00AM-11:00AM: Abstract Number: 1374

Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival

9:00AM-11:00AM: Abstract Number: 1528

Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients

9:00AM-11:00AM: Abstract Number: 1502

Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 0875

INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1208

Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 0919

Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level

9:00AM-11:00AM: Abstract Number: 0893

Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model

9:00AM-11:00AM: Abstract Number: 1431

Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results

9:00AM-11:00AM: Abstract Number: 0950

KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD)

9:00AM-11:00AM: Abstract Number: 0904

KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease

9:00AM-11:00AM: Abstract Number: 1538

Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades

9:00AM-11:00AM: Abstract Number: 1012

Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial

9:00AM-11:00AM: Abstract Number: 0895

Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus

9:00AM-11:00AM: Abstract Number: 1250

Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis

9:00AM-11:00AM: Abstract Number: 1383

Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study

9:00AM-11:00AM: Abstract Number: 1165

Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America

9:00AM-11:00AM: Abstract Number: 1331

Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial

9:00AM-11:00AM: Abstract Number: 1572

Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1434

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial

9:00AM-11:00AM: Abstract Number: 1435

Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial

9:00AM-11:00AM: Abstract Number: 1273

Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies

9:00AM-11:00AM: Abstract Number: 1537

Long-term Observational Study of Interstitial Lung Disease in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1505

Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies

9:00AM-11:00AM: Abstract Number: 1422

Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 1533

Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study

9:00AM-11:00AM: Abstract Number: 1229

Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus

9:00AM-11:00AM: Abstract Number: 1429

Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

9:00AM-11:00AM: Abstract Number: 0877

Loss of Transient Receptor Potential Channel 1 (TRPC1) Links Regulation of Intracellular Calcium to Cellular Senescence and Leads to Development of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1389

Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 0905

Low-Density Granulocytes and Neutrophil Extracellular Traps in Incomplete Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1267

Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1022

Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)

9:00AM-11:00AM: Abstract Number: 1464

Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1501

Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE

9:00AM-11:00AM: Abstract Number: 1180

Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality

9:00AM-11:00AM: Abstract Number: 0944

Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis

9:00AM-11:00AM: Abstract Number: 1345

Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy

9:00AM-11:00AM: Abstract Number: 1551

Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 0986

Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea

9:00AM-11:00AM: Abstract Number: 1057

Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data

9:00AM-11:00AM: Abstract Number: 1236

Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 1224

Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic

9:00AM-11:00AM: Abstract Number: 0876

Metabolomic Analysis Reveals Associations Between Calcium Crystals and Metabolites in Osteoarthritic Synovial Tissue

9:00AM-11:00AM: Abstract Number: 1563

Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease

9:00AM-11:00AM: Abstract Number: 0885

Mice Fed a Well-formulated Ketogenic Diet After OA Induction Develop Worse OA Outcomes and Increased Pain Sensitivity

9:00AM-11:00AM: Abstract Number: 1521

Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1108

Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

9:00AM-11:00AM: Abstract Number: 0960

MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV

9:00AM-11:00AM: Abstract Number: 0871

Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease

9:00AM-11:00AM: Abstract Number: 1106

Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation

9:00AM-11:00AM: Abstract Number: 1009

More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid

9:00AM-11:00AM: Abstract Number: 1473

Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades

9:00AM-11:00AM: Abstract Number: 1403

MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients

9:00AM-11:00AM: Abstract Number: 1068

Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events

9:00AM-11:00AM: Abstract Number: 1276

Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1453

Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts

9:00AM-11:00AM: Abstract Number: 1529

Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 1138

Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies

9:00AM-11:00AM: Abstract Number: 1225

Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients

9:00AM-11:00AM: Abstract Number: 0994

Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias

9:00AM-11:00AM: Abstract Number: 1143

Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis

9:00AM-11:00AM: Abstract Number: 1278

Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability

9:00AM-11:00AM: Abstract Number: 0886

Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation

9:00AM-11:00AM: Abstract Number: 1261

Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0918

Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0971

Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)

9:00AM-11:00AM: Abstract Number: 1541

Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA

9:00AM-11:00AM: Abstract Number: 1251

Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital

9:00AM-11:00AM: Abstract Number: 1454

Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review

9:00AM-11:00AM: Abstract Number: 1339

Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0913

Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals

9:00AM-11:00AM: Abstract Number: 0902

Neutrophils in Systemic Lupus Erythematosus Demonstrate Heterogeneity Based on Sex

9:00AM-11:00AM: Abstract Number: 0948

Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 1071

No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)

9:00AM-11:00AM: Abstract Number: 1264

Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study

9:00AM-11:00AM: Abstract Number: 0954

Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ

9:00AM-11:00AM: Abstract Number: 1367

Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients

9:00AM-11:00AM: Abstract Number: 1493

Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission

9:00AM-11:00AM: Abstract Number: 1457

Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1372

Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab

9:00AM-11:00AM: Abstract Number: 1240

Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash

9:00AM-11:00AM: Abstract Number: 1386

Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis

9:00AM-11:00AM: Abstract Number: 1260

Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis

9:00AM-11:00AM: Abstract Number: 1002

Optimizing Rural Rheumatology Access: Collaborative Tele-Health Clinic Between University of North Carolina and Piedmont Health 1 Year Extension and Opportunities for Improvement

9:00AM-11:00AM: Abstract Number: 1254

Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)

9:00AM-11:00AM: Abstract Number: 1530

Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience

9:00AM-11:00AM: Abstract Number: 1078

Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression

9:00AM-11:00AM: Abstract Number: 1053

Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease

9:00AM-11:00AM: Abstract Number: 0967

Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer

9:00AM-11:00AM: Abstract Number: 1388

Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI

9:00AM-11:00AM: Abstract Number: 0906

Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients

9:00AM-11:00AM: Abstract Number: 1349

Paternal Effects of Anti-TNFs in Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1219

Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 1294

Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement

9:00AM-11:00AM: Abstract Number: 1332

Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)

9:00AM-11:00AM: Abstract Number: 1303

Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1166

Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020

9:00AM-11:00AM: Abstract Number: 1026

Patients’ Barriers to Total Joint Arthroplasty: Associations with the Orthopedic Consultation

9:00AM-11:00AM: Abstract Number: 1030

Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors

9:00AM-11:00AM: Abstract Number: 0867

Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1515

Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0929

Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms

9:00AM-11:00AM: Abstract Number: 1507

Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial

9:00AM-11:00AM: Abstract Number: 1247

Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial

9:00AM-11:00AM: Abstract Number: 1110

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

9:00AM-11:00AM: Abstract Number: 1514

Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders

9:00AM-11:00AM: Abstract Number: 0863

Phenotype and Energy Metabolism Differ Between Osteoarthritic Chondrocytes from Male Compared to Female Patients

9:00AM-11:00AM: Abstract Number: 1252

Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?

9:00AM-11:00AM: Abstract Number: 1134

Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 1363

Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills

9:00AM-11:00AM: Abstract Number: 1379

Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1187

Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA

9:00AM-11:00AM: Abstract Number: 1387

Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1492

Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab

9:00AM-11:00AM: Abstract Number: 1132

Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1508

Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1468

Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest

9:00AM-11:00AM: Abstract Number: 1390

Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study

9:00AM-11:00AM: Abstract Number: 1463

Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1107

Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy

9:00AM-11:00AM: Abstract Number: 1119

Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1506

Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB

9:00AM-11:00AM: Abstract Number: 1186

Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study

9:00AM-11:00AM: Abstract Number: 1478

Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1156

Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong

9:00AM-11:00AM: Abstract Number: 1044

Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts

9:00AM-11:00AM: Abstract Number: 1080

Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0977

Prevalence of Arthritis in the United States: National Estimates from a Population-based Study

9:00AM-11:00AM: Abstract Number: 1469

Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1238

Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1411

Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1275

Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 1472

Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience

9:00AM-11:00AM: Abstract Number: 1091

Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care

9:00AM-11:00AM: Abstract Number: 1487

Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1324

Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

9:00AM-11:00AM: Abstract Number: 1570

Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study

9:00AM-11:00AM: Abstract Number: 1173

Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 0920

Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB

9:00AM-11:00AM: Abstract Number: 1285

PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1161

Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models

9:00AM-11:00AM: Abstract Number: 0864

Proteomic Analysis of Circulating Neutrophils from Osteoarthritis Patients Shows Metabolic Dysregulation That Is Associated with Decreased Physiologic Apoptosis

9:00AM-11:00AM: Abstract Number: 1282

Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement

9:00AM-11:00AM: Abstract Number: 1329

R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0909

Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0999

Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization

9:00AM-11:00AM: Abstract Number: 1021

Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1212

Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1481

Racial Disparities in Lupus Nephritis: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 1391

Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care

9:00AM-11:00AM: Abstract Number: 0957

Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 0865

Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy

9:00AM-11:00AM: Abstract Number: 1319

Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients

9:00AM-11:00AM: Abstract Number: 0973

Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1181

Real-World Myositis Antibody Frequency and Patient Awareness

9:00AM-11:00AM: Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

9:00AM-11:00AM: Abstract Number: 1340

Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data

9:00AM-11:00AM: Abstract Number: 1018

Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases

9:00AM-11:00AM: Abstract Number: 0879

Recommendations for a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0959

Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1082

Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic

9:00AM-11:00AM: Abstract Number: 1128

Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review

9:00AM-11:00AM: Abstract Number: 1309

Refractory RA Patients for Targeted Therapies in Real Life

9:00AM-11:00AM: Abstract Number: 1172

Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse

9:00AM-11:00AM: Abstract Number: 1152

Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1277

Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 1024

Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry

9:00AM-11:00AM: Abstract Number: 1195

Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study

9:00AM-11:00AM: Abstract Number: 1313

Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1440

Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks

9:00AM-11:00AM: Abstract Number: 1519

Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1356

Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1348

Reproductive Outcomes for Women with Vasculitis

9:00AM-11:00AM: Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

9:00AM-11:00AM: Abstract Number: 1475

Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer

9:00AM-11:00AM: Abstract Number: 1151

Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1014

Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities

9:00AM-11:00AM: Abstract Number: 0989

Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort

9:00AM-11:00AM: Abstract Number: 0995

Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients

9:00AM-11:00AM: Abstract Number: 1299

Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission

9:00AM-11:00AM: Abstract Number: 1274

Rheumatoid Arthritis Patients, Achieving Low Disease Activity State or Remission, Still Demonstrate Significant Hand Disability, as Assessed by Functional Dexterity Test: A Disconnection Between CDAI and Functional Hand Assessment

9:00AM-11:00AM: Abstract Number: 1333

Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset

9:00AM-11:00AM: Abstract Number: 0987

Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)

9:00AM-11:00AM: Abstract Number: 1298

Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1479

Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study

9:00AM-11:00AM: Abstract Number: 1291

Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan

9:00AM-11:00AM: Abstract Number: 1455

Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1281

Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE

9:00AM-11:00AM: Abstract Number: 1485

Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0968

Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1073

Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1179

Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome

9:00AM-11:00AM: Abstract Number: 1512

Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial

9:00AM-11:00AM: Abstract Number: 1076

Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study

9:00AM-11:00AM: Abstract Number: 0874

RNA-Binding Proteins That Are Highly Expressed and Enriched in Healthy Cartilage but Suppressed in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0862

Role of CRTAC1 as a Biomarker of Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1114

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout

9:00AM-11:00AM: Abstract Number: 0917

Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1484

Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature

9:00AM-11:00AM: Abstract Number: 0941

RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1326

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study

9:00AM-11:00AM: Abstract Number: 1532

Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 1070

Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon

9:00AM-11:00AM: Abstract Number: 1314

Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA

9:00AM-11:00AM: Abstract Number: 0921

SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 0976

Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1470

SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 0901

Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1436

Secukinumab Demonstrates a Consistent Safety Profile in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Updated Pooled Safety Analysis from Clinical Trials

9:00AM-11:00AM: Abstract Number: 0891

Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies

9:00AM-11:00AM: Abstract Number: 1256

Self-esteem and Body Image of Young People with Rheumatic Diseases: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1178

Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter

9:00AM-11:00AM: Abstract Number: 1206

Self-Perceptions of Aging and Physical Activity in Older Adults with Arthritis: Does General Health Matter?

9:00AM-11:00AM: Abstract Number: 1200

Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain

9:00AM-11:00AM: Abstract Number: 1346

Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls

9:00AM-11:00AM: Abstract Number: 1162

Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1227

Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1064

Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination

9:00AM-11:00AM: Abstract Number: 1117

Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

9:00AM-11:00AM: Abstract Number: 1217

Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey

9:00AM-11:00AM: Abstract Number: 1353

Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study

9:00AM-11:00AM: Abstract Number: 0958

Shared Genetic Susceptibility Between Systemic Sclerosis and Primary Biliary Cholangitis: Analyses from Genome-Wide Association Studies

9:00AM-11:00AM: Abstract Number: 1352

Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study

9:00AM-11:00AM: Abstract Number: 1293

Single Camera Hand Motion Capturing as a Digital Biomarker for Disease Activity in Rheumatoid Arthritis Using Computer Vision: The Proof-of-Concept MeFisto Study

9:00AM-11:00AM: Abstract Number: 0951

Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance

9:00AM-11:00AM: Abstract Number: 0859

Single Injection AAV2-hFGF18 Demonstrates Superior Safety and Efficacy over Repeat rhFGF18 Protein Injections in a Model of Induced Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0926

Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0892

Single-Cell RNA Sequencing Reveals Keratinocytes and Fibroblasts Drive Hippo and TGFb Dysregulation and Fibrosis in Epidermal Overexpression of VGLL3 in Cutaneous Lupus

9:00AM-11:00AM: Abstract Number: 1027

Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis

9:00AM-11:00AM: Abstract Number: 1220

Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ)

9:00AM-11:00AM: Abstract Number: 1376

SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up

9:00AM-11:00AM: Abstract Number: 0928

Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab

9:00AM-11:00AM: Abstract Number: 1445

SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1029

Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort

9:00AM-11:00AM: Abstract Number: 0935

Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling

9:00AM-11:00AM: Abstract Number: 1185

Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients

9:00AM-11:00AM: Abstract Number: 0911

Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations

9:00AM-11:00AM: Abstract Number: 0890

Specificity of Brain-Intrinsic and Hematopoietic-Derived Mechanisms in Mediating Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1306

Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0897

Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model

9:00AM-11:00AM: Abstract Number: 1231

Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis

9:00AM-11:00AM: Abstract Number: 0993

Successful Implementation of a New Patient Video Triage Program

9:00AM-11:00AM: Abstract Number: 1397

Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

9:00AM-11:00AM: Abstract Number: 1328

Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation

9:00AM-11:00AM: Abstract Number: 1380

Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes

9:00AM-11:00AM: Abstract Number: 0872

Synovial 5-LOX-Derived Oxylipins Define a B Cell-Enriched Synovium

9:00AM-11:00AM: Abstract Number: 0878

Synovial Fibroblasts Undergo a Phenotypic Shift from Early- to Late-stage Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1370

Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration

9:00AM-11:00AM: Abstract Number: 1456

Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens

9:00AM-11:00AM: Abstract Number: 0982

Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants

9:00AM-11:00AM: Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1280

Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1357

Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 0964

Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling

9:00AM-11:00AM: Abstract Number: 1516

Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity

9:00AM-11:00AM: Abstract Number: 1311

T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1575

Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study

9:00AM-11:00AM: Abstract Number: 1120

Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients

9:00AM-11:00AM: Abstract Number: 0870

Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1491

Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 0896

Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1007

Telehealth Conversion: A Strategy for Optimizing Ambulatory Access

9:00AM-11:00AM: Abstract Number: 1005

Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial

9:00AM-11:00AM: Abstract Number: 1004

Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario

9:00AM-11:00AM: Abstract Number: 1406

Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data

9:00AM-11:00AM: Abstract Number: 0980

Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 0933

The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1338

The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort

9:00AM-11:00AM: Abstract Number: 0861

The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain

9:00AM-11:00AM: Abstract Number: 1266

The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1222

The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM)

9:00AM-11:00AM: Abstract Number: 1401

The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA

9:00AM-11:00AM: Abstract Number: 1543

The Association of Frailty with Outcomes in Patients with Vasculitis

9:00AM-11:00AM: Abstract Number: 1193

The Association of Peak Forces and Loading Rates During Walking with MRI-Based Structural Worsening of the Knee: The Multicenter Osteoarthritis Study

9:00AM-11:00AM: Abstract Number: 1237

The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE

9:00AM-11:00AM: Abstract Number: 1542

The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study

9:00AM-11:00AM: Abstract Number: 0966

The Burden of Oligoarticular Psoriatic Arthritis in the United States

9:00AM-11:00AM: Abstract Number: 0894

The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light

9:00AM-11:00AM: Abstract Number: 1116

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System

9:00AM-11:00AM: Abstract Number: 1342

The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1033

The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1494

The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network

9:00AM-11:00AM: Abstract Number: 1524

The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1536

The Impact of COVID-19 Vaccination on ANCA Vasculitis Hospitalisations: A Perspective from Sydney Australia

9:00AM-11:00AM: Abstract Number: 1354

The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus

9:00AM-11:00AM: Abstract Number: 1269

The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes

9:00AM-11:00AM: Abstract Number: 0932

The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing

9:00AM-11:00AM: Abstract Number: 1046

The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 0922

The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles

9:00AM-11:00AM: Abstract Number: 1118

The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project

9:00AM-11:00AM: Abstract Number: 1253

The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease

9:00AM-11:00AM: Abstract Number: 0945

The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1233

The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 1048

The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound

9:00AM-11:00AM: Abstract Number: 1135

The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients

9:00AM-11:00AM: Abstract Number: 1036

The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study

9:00AM-11:00AM: Abstract Number: 1257

The Psychological Experience of Work for People with Inflammatory Arthritis (IA)

9:00AM-11:00AM: Abstract Number: 1301

The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 1034

The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts

9:00AM-11:00AM: Abstract Number: 1375

The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1523

The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1574

The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 1209

The Role of Kinesiophobia on Ankylosing Spondylitis Disease Activity, Exercise Habits, and Quality of Life

9:00AM-11:00AM: Abstract Number: 0883

The Role of Plasmin and Fibrinolysis Pathways in Osteoarthritis

9:00AM-11:00AM: Abstract Number: 0898

The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction

9:00AM-11:00AM: Abstract Number: 1122

The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy

9:00AM-11:00AM: Abstract Number: 1378

The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 1410

The Use of the ASAS Referral Criteria Together with Increased Education and Training of Its Use Improves Delay to Diagnosis of Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1554

Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study

9:00AM-11:00AM: Abstract Number: 1248

Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry

9:00AM-11:00AM: Abstract Number: 0981

Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 1571

Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 0962

Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma

9:00AM-11:00AM: Abstract Number: 0914

Transcription Factor RFX1 Promotes M1 Macrophage Polarization in Systemic Lupus Erythematosus via Regulating APOBEC3A

9:00AM-11:00AM: Abstract Number: 1167

Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)

9:00AM-11:00AM: Abstract Number: 0961

Transcriptomic Analysis of Scleroderma Monocytes Identifies Distinct Clinically Relevant Clusters and Novel Genes Associated with Disease Complications

9:00AM-11:00AM: Abstract Number: 1522

Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis

9:00AM-11:00AM: Abstract Number: 1369

Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey

9:00AM-11:00AM: Abstract Number: 1549

Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data

9:00AM-11:00AM: Abstract Number: 1182

Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1489

Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study

9:00AM-11:00AM: Abstract Number: 0991

Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database

9:00AM-11:00AM: Abstract Number: 1399

Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data

9:00AM-11:00AM: Abstract Number: 1513

Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019

9:00AM-11:00AM: Abstract Number: 1243

Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1149

Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series

9:00AM-11:00AM: Abstract Number: 0969

Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 1045

Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1312

Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry

9:00AM-11:00AM: Abstract Number: 1204

Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies

9:00AM-11:00AM: Abstract Number: 1052

Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

9:00AM-11:00AM: Abstract Number: 1205

Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study

9:00AM-11:00AM: Abstract Number: 1153

Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches

9:00AM-11:00AM: Abstract Number: 0952

Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21

9:00AM-11:00AM: Abstract Number: 1459

Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual

9:00AM-11:00AM: Abstract Number: 1271

Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 0916

Upregulation of the M-CSF Receptor on Non-Classical Monocytes from SLE Patients as an Indicator for Premature Monocyte Aging

9:00AM-11:00AM: Abstract Number: 1111

Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 0979

Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1006

Use of Implementation Strategies to Promote Adherence of Knee Osteoarthritis Guidelines and Improve Patient Outcomes: A Systematic Review

9:00AM-11:00AM: Abstract Number: 1214

Using Patient Self-Reported Measures to Predict All-Cause Hospitalization in a Population-Based Lupus Cohort

9:00AM-11:00AM: Abstract Number: 1213

Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits

9:00AM-11:00AM: Abstract Number: 1085

Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

9:00AM-11:00AM: Abstract Number: 1203

Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision

9:00AM-11:00AM: Abstract Number: 0860

Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation

9:00AM-11:00AM: Abstract Number: 0974

Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy

9:00AM-11:00AM: Abstract Number: 1051

Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis

9:00AM-11:00AM: Abstract Number: 1545

Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1228

Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach

9:00AM-11:00AM: Abstract Number: 1305

Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1061

Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology

9:00AM-11:00AM: Abstract Number: 1443

Vasculitis Associations Among Patients with Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 1259

Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1279

What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference

9:00AM-11:00AM: Abstract Number: 1385

Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers

9:00AM-11:00AM: Abstract Number: 0996

Will Patients Engage with Digital Technologies as Part of Routine Healthcare?

9:00AM-11:00AM: Abstract Number: 1304

Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy

9:00AM-11:00AM: Abstract Number: 1190

Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire

9:00AM-11:00AM: Abstract Number: 1499

Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study

11:00AM-12:30PM: Abstract Number: 1583

Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)

11:00AM-12:30PM: Abstract Number: 1580

CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon

11:00AM-12:30PM: Abstract Number: 1584

Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study

11:00AM-12:30PM: Abstract Number: 1581

Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes

11:00AM-12:30PM: Abstract Number: 1582

Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data

11:00AM-12:30PM: Abstract Number: 1579

Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 1596

A Cell and Transcriptomic Atlas of the Infrapatellar Fat Pad from Patients with Knee Osteoarthritis: Identification of an Obesity-Associated Transcriptomic Signature

2:00PM-3:30PM: Abstract Number: 1654

A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

2:00PM-3:30PM: Abstract Number: 1645

Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort

2:00PM-3:30PM: Abstract Number: 1647

Association Between Vascular FDG Uptake at Diagnosis and Evolution in Aortic Dimensions in Giant Cell Arteritis: A Prospective Study

2:00PM-3:30PM: Abstract Number: 1609

Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study

2:00PM-3:30PM: Abstract Number: 1607

Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 1590

Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist

2:00PM-3:30PM: Abstract Number: 1651

Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1620

Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab

2:00PM-3:30PM: Abstract Number: 1638

CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden

2:00PM-3:30PM: Abstract Number: 1626

Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study

2:00PM-3:30PM: Abstract Number: 1593

Combining Single-cell RNA Sequencing and Population-based Studies Reveals Hand Osteoarthritis-associated Chondrocyte Subpopulations and Pathways

2:00PM-3:30PM: Abstract Number: 1617

Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022

2:00PM-3:30PM: Abstract Number: 1631

Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 1605

Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

2:00PM-3:30PM: Abstract Number: 1591

Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis

2:00PM-3:30PM: Abstract Number: 1636

Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

2:00PM-3:30PM: Abstract Number: 1635

Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies

2:00PM-3:30PM: Abstract Number: 1585

Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure

2:00PM-3:30PM: Abstract Number: 1612

Design and Validation of a Comparator for Randomized Controlled Trials of a Digital Cognitive Behavioral Therapy

2:00PM-3:30PM: Abstract Number: 1623

Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort

2:00PM-3:30PM: Abstract Number: 1610

Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial

2:00PM-3:30PM: Abstract Number: 1633

Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease

2:00PM-3:30PM: Abstract Number: 1589

Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis

2:00PM-3:30PM: Abstract Number: 1648

EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update

2:00PM-3:30PM: Abstract Number: 1643

Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 1604

First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

2:00PM-3:30PM: Abstract Number: 1649

Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis

2:00PM-3:30PM: Abstract Number: 1616

Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies

2:00PM-3:30PM: Abstract Number: 1642

Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort

2:00PM-3:30PM: Abstract Number: 1625

Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning

2:00PM-3:30PM: Abstract Number: 1637

IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity

2:00PM-3:30PM: Abstract Number: 1632

Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care

2:00PM-3:30PM: Abstract Number: 1603

Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes

2:00PM-3:30PM: Abstract Number: 1601

Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus

2:00PM-3:30PM: Abstract Number: 1618

Intervention to Improve Medication Adherence Among Patients with SLE

2:00PM-3:30PM: Abstract Number: 1634

Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

2:00PM-3:30PM: Abstract Number: 1586

Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing

2:00PM-3:30PM: Abstract Number: 1652

Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders

2:00PM-3:30PM: Abstract Number: 1621

Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma

2:00PM-3:30PM: Abstract Number: 1592

Memantine Attenuates the Development of Osteoarthritis by Blocking NMDA Receptor Mediated Calcium Overload and Chondrocyte Senescence

2:00PM-3:30PM: Abstract Number: 1627

Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 1611

Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study

2:00PM-3:30PM: Abstract Number: 1587

Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity

2:00PM-3:30PM: Abstract Number: 1588

Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing

2:00PM-3:30PM: Abstract Number: 1622

Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality

2:00PM-3:30PM: Abstract Number: 1602

NADPH Oxidase Exerts a B Cell-intrinsic Contribution to Lupus Risk by Modulating Endosomal Toll-like Receptor (TLR) Signals

2:00PM-3:30PM: Abstract Number: 1656

Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)

2:00PM-3:30PM: Abstract Number: 1650

Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis

2:00PM-3:30PM: Abstract Number: 1594

Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis

2:00PM-3:30PM: Abstract Number: 1630

Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 1629

Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative

2:00PM-3:30PM: Abstract Number: 1595

Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration

2:00PM-3:30PM: Abstract Number: 1608

Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

2:00PM-3:30PM: Abstract Number: 1639

PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease

2:00PM-3:30PM: Abstract Number: 1640

Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network

2:00PM-3:30PM: Abstract Number: 1606

Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation

2:00PM-3:30PM: Abstract Number: 1624

Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study

2:00PM-3:30PM: Abstract Number: 1619

Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis

2:00PM-3:30PM: Abstract Number: 1599

Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus

2:00PM-3:30PM: Abstract Number: 1598

Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis

2:00PM-3:30PM: Abstract Number: 1597

Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 1613

Tetrodotoxin Sensitive Nav1.7 Sodium Channel SCN9A Gene Polymorphism rs6754031(T >G) Is Associated with Fibromyalgia

2:00PM-3:30PM: Abstract Number: 1644

The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients

2:00PM-3:30PM: Abstract Number: 1628

The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis

2:00PM-3:30PM: Abstract Number: 1646

The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis

2:00PM-3:30PM: Abstract Number: 1641

The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?

2:00PM-3:30PM: Abstract Number: 1615

Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations

2:00PM-3:30PM: Abstract Number: 1614

Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial

2:00PM-3:30PM: Abstract Number: 1600

Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes

2:00PM-3:30PM: Abstract Number: 1653

Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?

2:00PM-3:30PM: Abstract Number: 1655

Usability Testing of JIActiv, an Instagram-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis

4:00PM-5:30PM: Abstract Number: 1691

16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast

4:00PM-5:30PM: Abstract Number: 1686

Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting

4:00PM-5:30PM: Abstract Number: 1690

Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study

4:00PM-5:30PM: Abstract Number: 1672

Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study

4:00PM-5:30PM: Abstract Number: 1693

Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures

4:00PM-5:30PM: Abstract Number: 1668

Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes

4:00PM-5:30PM: Abstract Number: 1659

Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis

4:00PM-5:30PM: Abstract Number: 1667

Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry

4:00PM-5:30PM: Abstract Number: 1662

Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

4:00PM-5:30PM: Abstract Number: 1663

Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

4:00PM-5:30PM: Abstract Number: 1678

Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis

4:00PM-5:30PM: Abstract Number: 1689

Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

4:00PM-5:30PM: Abstract Number: 1679

Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis

4:00PM-5:30PM: Abstract Number: 1665

Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

4:00PM-5:30PM: Abstract Number: 1704

Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma

4:00PM-5:30PM: Abstract Number: 1670

Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae

4:00PM-5:30PM: Abstract Number: 1664

Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis

4:00PM-5:30PM: Abstract Number: 1669

High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study

4:00PM-5:30PM: Abstract Number: 1698

High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis

4:00PM-5:30PM: Abstract Number: 1673

Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

4:00PM-5:30PM: Abstract Number: 1699

Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis

4:00PM-5:30PM: Abstract Number: 1700

Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis

4:00PM-5:30PM: Abstract Number: 1703

Increased Mortality and Cardiovascular Events in Male Patients with Systemic Sclerosis: Left Ventricular Global Longitudinal Strain as Possible Screening Tool

4:00PM-5:30PM: Abstract Number: 1692

Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)

4:00PM-5:30PM: Abstract Number: 1688

Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks

4:00PM-5:30PM: Abstract Number: 1657

Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution

4:00PM-5:30PM: Abstract Number: 1697

Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort

4:00PM-5:30PM: Abstract Number: 1683

Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO

4:00PM-5:30PM: Abstract Number: 1696

Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

4:00PM-5:30PM: Abstract Number: 1702

Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation

4:00PM-5:30PM: Abstract Number: 1682

Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block

4:00PM-5:30PM: Abstract Number: 1674

Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group

4:00PM-5:30PM: Abstract Number: 1687

Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials

4:00PM-5:30PM: Abstract Number: 1695

Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis

4:00PM-5:30PM: Abstract Number: 1685

SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients

4:00PM-5:30PM: Abstract Number: 1661

Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin

4:00PM-5:30PM: Abstract Number: 1660

Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways

4:00PM-5:30PM: Abstract Number: 1675

Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors

4:00PM-5:30PM: Abstract Number: 1681

Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers

4:00PM-5:30PM: Abstract Number: 1684

The Impact of Pregnancy Timing on Outcomes in SLE

4:00PM-5:30PM: Abstract Number: 1658

Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis

4:00PM-5:30PM: Abstract Number: 1666

TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling

4:00PM-5:30PM: Abstract Number: 1676

Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology

4:00PM-5:30PM: Abstract Number: 1694

Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE

4:00PM-5:30PM: Abstract Number: 1701

Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines

4:00PM-5:30PM: Abstract Number: 1677

Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial

4:00PM-5:30PM: Abstract Number: 1671

Use of Metagenomic Microbial Plasma Cell-Free DNA Next-Generation Sequencing Assay in Outpatient Rheumatology Practice

4:00PM-5:30PM: Abstract Number: 1680

What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?

9:00AM-11:00AM: Abstract Number: 2394

18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry

9:00AM-11:00AM: Abstract Number: 2019

2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

9:00AM-11:00AM: Abstract Number: 2167

24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)

9:00AM-11:00AM: Abstract Number: 1894

3-Dimensional Regional Variation in Inter-rater Reliability of Bone Marrow Lesion Scoring in the Knee

9:00AM-11:00AM: Abstract Number: L07

3-year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Rheumatoid Arthritis Patients in Sustained Remission: A Multicenter Randomized Trial

9:00AM-11:00AM: Abstract Number: 1723

3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity

9:00AM-11:00AM: Abstract Number: 2185

35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study

9:00AM-11:00AM: Abstract Number: 1731

A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis

9:00AM-11:00AM: Abstract Number: 2071

A Consensus Based Shoulder Examination for Rheumatology Training

9:00AM-11:00AM: Abstract Number: 2077

A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1876

A Deep Learning System for Automated Assessing Microcirculation Abnormalities in Nailfold Capillaroscopy Images of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1846

A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders

9:00AM-11:00AM: Abstract Number: 2356

A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2062

A Mental Health Workshop for Pediatric Rheumatology Fellows

9:00AM-11:00AM: Abstract Number: 2067

A New Tool Assessing Trainees’ Interventional Musculoskeletal Ultrasound Skills

9:00AM-11:00AM: Abstract Number: 1747

A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells

9:00AM-11:00AM: Abstract Number: 1728

A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

9:00AM-11:00AM: Abstract Number: 1779

A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation

9:00AM-11:00AM: Abstract Number: 1920

A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS005 in Patients with Moderate to Severe Psoriasis

9:00AM-11:00AM: Abstract Number: 2055

A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study

9:00AM-11:00AM: Abstract Number: 1997

A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

9:00AM-11:00AM: Abstract Number: 2379

A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy

9:00AM-11:00AM: Abstract Number: 2402

A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center

9:00AM-11:00AM: Abstract Number: 1940

A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 2401

A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1835

A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents

9:00AM-11:00AM: Abstract Number: 2085

A Survey on Giant Cell Arteritis-Related Knowledge Among Internal Medicine Residents

9:00AM-11:00AM: Abstract Number: 2211

A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 1714

Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling

9:00AM-11:00AM: Abstract Number: 1893

Abnormalities Detected with [18F]-FDG-PET/CT Imaging in VEXAS Syndrome

9:00AM-11:00AM: Abstract Number: 2239

Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1737

ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA

9:00AM-11:00AM: Abstract Number: 1753

Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint

9:00AM-11:00AM: Abstract Number: 2090

Adaptation of the Making it WorkTM for People with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2142

Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors

9:00AM-11:00AM: Abstract Number: 2146

After JAK Inhibitor Failure, “Switching” or “Cycling”?

9:00AM-11:00AM: Abstract Number: 2272

Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States

9:00AM-11:00AM: Abstract Number: 1810

Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels

9:00AM-11:00AM: Abstract Number: 2329

AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo

9:00AM-11:00AM: Abstract Number: 2041

An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1729

An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2323

An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health

9:00AM-11:00AM: Abstract Number: L13

An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results

9:00AM-11:00AM: Abstract Number: 1735

An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry

9:00AM-11:00AM: Abstract Number: 1929

Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience

9:00AM-11:00AM: Abstract Number: L01

Analysis of 245,388 Diverse Participants in the NIH All of Us Cohort Identifies VEXAS Resiliency in UBA1 M41L Somatic Mutation Carriers

9:00AM-11:00AM: Abstract Number: 1933

Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 2381

ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain

9:00AM-11:00AM: Abstract Number: 1715

Androgen Treatment Exhibits a Protective Role Against Focal Erosions in TNF-Induced Inflammatory Arthritis in Mice

9:00AM-11:00AM: Abstract Number: 2193

Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement

9:00AM-11:00AM: Abstract Number: 1931

Anti-Ku Antibodies: A Case Series

9:00AM-11:00AM: Abstract Number: 1952

Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series

9:00AM-11:00AM: Abstract Number: 1961

Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome

9:00AM-11:00AM: Abstract Number: 2283

Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness

9:00AM-11:00AM: Abstract Number: 2210

Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1764

Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2400

Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept

9:00AM-11:00AM: Abstract Number: 2303

Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?

9:00AM-11:00AM: Abstract Number: 1844

Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey

9:00AM-11:00AM: Abstract Number: 2136

Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice

9:00AM-11:00AM: Abstract Number: 1727

Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice

9:00AM-11:00AM: Abstract Number: 1919

Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series

9:00AM-11:00AM: Abstract Number: 1879

Artificial Intelligence for the Detection of Sacroiliitis on Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1903

Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry

9:00AM-11:00AM: Abstract Number: 1813

Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses

9:00AM-11:00AM: Abstract Number: 2315

Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London

9:00AM-11:00AM: Abstract Number: 2037

Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology

9:00AM-11:00AM: Abstract Number: 1870

Assessing the Appropriateness of Imaging Modalities in Primary Care for Low Back Pain and Their Impact on Outcomes: A Retrospective Observational Study in a Single Center in Trenton

9:00AM-11:00AM: Abstract Number: 1900

Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps

9:00AM-11:00AM: Abstract Number: 2034

Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire

9:00AM-11:00AM: Abstract Number: 2296

Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey

9:00AM-11:00AM: Abstract Number: 2187

Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1798

Association Between Knee Osteoarthritis and Mortality: A Serial Propensity Score-matched Cohort Study

9:00AM-11:00AM: Abstract Number: 1992

Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials

9:00AM-11:00AM: Abstract Number: 2096

Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure

9:00AM-11:00AM: Abstract Number: 2290

Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model

9:00AM-11:00AM: Abstract Number: 1799

Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain

9:00AM-11:00AM: Abstract Number: 2194

Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients

9:00AM-11:00AM: Abstract Number: 2222

Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides

9:00AM-11:00AM: Abstract Number: 2127

Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer

9:00AM-11:00AM: Abstract Number: 2139

Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 1763

Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up

9:00AM-11:00AM: Abstract Number: 2070

Augmenting Medical Education: An Evaluation of GPT-4 and ChatGPT in Answering Rheumatology Questions from the Spanish Medical Licensing Examination

9:00AM-11:00AM: Abstract Number: 2134

Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA

9:00AM-11:00AM: Abstract Number: 1706

Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2208

Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States

9:00AM-11:00AM: Abstract Number: 2010

B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort

9:00AM-11:00AM: Abstract Number: 2021

Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy

9:00AM-11:00AM: Abstract Number: 2250

Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies

9:00AM-11:00AM: Abstract Number: 2252

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study

9:00AM-11:00AM: Abstract Number: 2230

Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year

9:00AM-11:00AM: Abstract Number: 2255

Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial

9:00AM-11:00AM: Abstract Number: 2249

Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 2149

Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors

9:00AM-11:00AM: Abstract Number: 1780

Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study

9:00AM-11:00AM: Abstract Number: 1829

Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome

9:00AM-11:00AM: Abstract Number: 1930

Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series

9:00AM-11:00AM: Abstract Number: 2004

Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study

9:00AM-11:00AM: Abstract Number: 2258

Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task

9:00AM-11:00AM: Abstract Number: 1824

Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2261

Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study

9:00AM-11:00AM: Abstract Number: 2001

Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis

9:00AM-11:00AM: Abstract Number: 2411

C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET

9:00AM-11:00AM: Abstract Number: 2370

C5 as a Genetic Marker for Discriminating Between IgA Vasculitis and IgA Nephropathy?

9:00AM-11:00AM: Abstract Number: 2389

Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab

9:00AM-11:00AM: Abstract Number: 2215

Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 2133

Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI

9:00AM-11:00AM: Abstract Number: 1874

Cartilage Thickness Measures Are More Responsive Than Cartilage Area Loss Measures: A Comparison of Quantitative and Semi-quantitative Cartilage Assessments from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 1945

Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals

9:00AM-11:00AM: Abstract Number: 1711

CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation

9:00AM-11:00AM: Abstract Number: 2176

Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1873

Cervical Spine Involvement in Axial Spondyloarthritis. Radiographic Characteristics and Associated Factors

9:00AM-11:00AM: Abstract Number: 2306

Changes in Rheumatology Disease Measures After Initiation of Belimumab Treatment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2319

Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry

9:00AM-11:00AM: Abstract Number: 2392

Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2177

Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 1944

Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre

9:00AM-11:00AM: Abstract Number: 2390

Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6

9:00AM-11:00AM: Abstract Number: 2367

Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1745

Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo

9:00AM-11:00AM: Abstract Number: 1756

Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2364

Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1908

Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 1987

Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 2221

Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers

9:00AM-11:00AM: Abstract Number: 2013

Clinical Characteristics and Risk Factors Associated with Fragility Fractures in Patients with Primary and Idiopathic Mast Cell Activation Syndromes

9:00AM-11:00AM: Abstract Number: 2375

Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7

9:00AM-11:00AM: Abstract Number: 2383

Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1916

Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype

9:00AM-11:00AM: Abstract Number: 1819

Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data

9:00AM-11:00AM: Abstract Number: 1809

Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2121

Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1921

Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department

9:00AM-11:00AM: Abstract Number: 1841

Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort

9:00AM-11:00AM: Abstract Number: 2039

Clinical, Immunologic, and Genetic Characteristics in Patients with Syndrome of Undifferentiated Recurrent Fevers (SURF)

9:00AM-11:00AM: Abstract Number: 2105

Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1977

Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)

9:00AM-11:00AM: Abstract Number: 2171

Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?

9:00AM-11:00AM: Abstract Number: 1895

Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies

9:00AM-11:00AM: Abstract Number: 2079

Comparative Analysis of Teledidactic and On-Campus Training in Musculoskeletal Ultrasound – the TELMUS Study

9:00AM-11:00AM: Abstract Number: 2008

Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

9:00AM-11:00AM: Abstract Number: 2307

Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization

9:00AM-11:00AM: Abstract Number: 2219

Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2125

Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes

9:00AM-11:00AM: Abstract Number: 2097

Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque

9:00AM-11:00AM: Abstract Number: 2416

Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study

9:00AM-11:00AM: Abstract Number: 2314

Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1974

Comparison of Gait Spatiotemporal Measures Between Patients with Insertional Achilles Tendinopathy or Midportion Achilles Tendinopathy

9:00AM-11:00AM: Abstract Number: 2083

Compiled Verbal Feedback as a Novel Mechanism for Faculty Feedback from Rheumatology Fellows-in-Training

9:00AM-11:00AM: Abstract Number: 1818

Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S

9:00AM-11:00AM: Abstract Number: 2423

Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2409

Concordance of Relapse Symptoms with Initial Baseline Presentation Features Among Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2158

Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON

9:00AM-11:00AM: Abstract Number: 2098

Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2122

Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study

9:00AM-11:00AM: Abstract Number: 2002

Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

9:00AM-11:00AM: Abstract Number: 2169

Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

9:00AM-11:00AM: Abstract Number: 1886

Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1938

Cranial Nerve Manifestations in Sarcoidosis Associated with Lymphoma, Non-facial Paralysis, and Other Neurologic Disorders

9:00AM-11:00AM: Abstract Number: 2074

Creation and Dissemination of a Near-Peer Rheumatology Fellowship Bootcamp

9:00AM-11:00AM: Abstract Number: 2060

Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology

9:00AM-11:00AM: Abstract Number: 1995

Cross-cultural Adaptation, Reduction, and Validation of the Turkish Versions of the Flare-OA Questionnaire for Hip and Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2393

CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap

9:00AM-11:00AM: Abstract Number: 2332

Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 2333

Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial

9:00AM-11:00AM: Abstract Number: L10

Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement

9:00AM-11:00AM: Abstract Number: 2365

Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression

9:00AM-11:00AM: Abstract Number: 1986

Deep Immunophenotyping of Osteoarthritis Patients Demonstrates Baseline Alterations in Monocyte Populations in OA, Dendritic Cell Subpopulations Among Radiographic Progressors, and Th17 Cells Among Pain Progressors

9:00AM-11:00AM: Abstract Number: 1881

Deep Learning Approaches to Rheumatoid Arthritis Severity Prognosis

9:00AM-11:00AM: Abstract Number: 2335

Defining a Basket Population for ANA+ Arthritis Trials

9:00AM-11:00AM: Abstract Number: 2082

Delivery of Rheumatology Education to Internal Medicine Residents in Rwanda: Evaluation of a New Virtual Rheumatology Course Supplemented by On-site Clinical Teaching

9:00AM-11:00AM: Abstract Number: 1848

Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1784

Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model

9:00AM-11:00AM: Abstract Number: 1837

Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia

9:00AM-11:00AM: Abstract Number: 1843

Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning

9:00AM-11:00AM: Abstract Number: 2253

Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast

9:00AM-11:00AM: Abstract Number: 2328

Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 2202

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers

9:00AM-11:00AM: Abstract Number: 2026

Developing a Guided Joint Self-Exam for Rheumatoid Arthritis Patients to Use in Telehealth-Delivered Care

9:00AM-11:00AM: Abstract Number: 2027

Developing and Implementing a Pilot Educational Intervention to Improve Readiness for Self-Management Among Patients with Rheumatic Diseases in Uganda

9:00AM-11:00AM: Abstract Number: 2048

Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)

9:00AM-11:00AM: Abstract Number: 1833

Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

9:00AM-11:00AM: Abstract Number: 1845

Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases

9:00AM-11:00AM: Abstract Number: 2022

Development of an mHealth App for Lupus: Insights from a Human-Centered Design Approach

9:00AM-11:00AM: Abstract Number: 2018

Development of an Osteoporosis Treatment Gap Dashboard

9:00AM-11:00AM: Abstract Number: 2184

Development of Salivary Gland Organoids to Study Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 1910

Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2101

Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method

9:00AM-11:00AM: Abstract Number: 2197

Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors

9:00AM-11:00AM: Abstract Number: 2396

Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1877

Diagnostic Yield of 18F-FDG PET-CT for Large Vessel Involvement in Patients with Suspected Giant Cell Arteritis and Negative Temporal Artery Biopsy

9:00AM-11:00AM: Abstract Number: L05

DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis

9:00AM-11:00AM: Abstract Number: 2224

Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes

9:00AM-11:00AM: Abstract Number: 2251

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study

9:00AM-11:00AM: Abstract Number: 2266

Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception

9:00AM-11:00AM: Abstract Number: 2234

Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities

9:00AM-11:00AM: Abstract Number: 1965

Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study

9:00AM-11:00AM: Abstract Number: 2205

Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients

9:00AM-11:00AM: Abstract Number: 2263

Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 2179

Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey

9:00AM-11:00AM: Abstract Number: 2330

Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis

9:00AM-11:00AM: Abstract Number: 2304

Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study

9:00AM-11:00AM: Abstract Number: 1725

Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model

9:00AM-11:00AM: Abstract Number: 2040

Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)

9:00AM-11:00AM: Abstract Number: 1976

Distribution and Validity of Proposed Disability Categories from the Short-Valued Life Activities Questionnaire

9:00AM-11:00AM: Abstract Number: 2148

Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial

9:00AM-11:00AM: Abstract Number: 1975

Do You Believe in Exercise for Osteoarthritis? Exploring Differences in Participant Characteristics with Treatment Beliefs in Exercise for Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2321

Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort

9:00AM-11:00AM: Abstract Number: 2123

Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2245

Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study

9:00AM-11:00AM: Abstract Number: 1770

Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1812

Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain

9:00AM-11:00AM: Abstract Number: 1750

Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses

9:00AM-11:00AM: Abstract Number: 1853

Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care

9:00AM-11:00AM: Abstract Number: L08

Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation

9:00AM-11:00AM: Abstract Number: 2228

Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment

9:00AM-11:00AM: Abstract Number: 2284

Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea

9:00AM-11:00AM: Abstract Number: 1891

Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial

9:00AM-11:00AM: Abstract Number: 1982

Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1963

Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis

9:00AM-11:00AM: Abstract Number: 2316

Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study

9:00AM-11:00AM: Abstract Number: 2317

Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study

9:00AM-11:00AM: Abstract Number: 1831

Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia

9:00AM-11:00AM: Abstract Number: 2311

Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene

9:00AM-11:00AM: Abstract Number: 2418

Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment

9:00AM-11:00AM: Abstract Number: 2003

Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis

9:00AM-11:00AM: Abstract Number: 1990

Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2007

Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study

9:00AM-11:00AM: Abstract Number: 2151

Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 2153

Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: L14

Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

9:00AM-11:00AM: Abstract Number: L09

Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: L03

Efficacy and Safety of Targeted Therapies in VEXAS Syndrome: Retrospective Study from the French VEXAS Group

9:00AM-11:00AM: Abstract Number: 2326

Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g

9:00AM-11:00AM: Abstract Number: L12

Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2165

Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up

9:00AM-11:00AM: Abstract Number: 2191

Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease

9:00AM-11:00AM: Abstract Number: 2347

Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials

9:00AM-11:00AM: Abstract Number: 1937

Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 2143

Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study

9:00AM-11:00AM: Abstract Number: 1861

Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

9:00AM-11:00AM: Abstract Number: 2156

Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study

9:00AM-11:00AM: Abstract Number: 2000

Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

9:00AM-11:00AM: Abstract Number: 1836

Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium

9:00AM-11:00AM: Abstract Number: 2028

Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact

9:00AM-11:00AM: Abstract Number: 1717

Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2084

Enhancing Internal Medicine Curriculum: Key Rheumatology Themes in Inpatient Setting

9:00AM-11:00AM: Abstract Number: 2309

Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2376

Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: L04

EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2391

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register

9:00AM-11:00AM: Abstract Number: 2281

Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 2269

Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study

9:00AM-11:00AM: Abstract Number: 2061

Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA)

9:00AM-11:00AM: Abstract Number: 1954

Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center

9:00AM-11:00AM: Abstract Number: 1834

Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort

9:00AM-11:00AM: Abstract Number: 1972

Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial

9:00AM-11:00AM: Abstract Number: 2106

Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls

9:00AM-11:00AM: Abstract Number: 2412

Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice

9:00AM-11:00AM: Abstract Number: 1860

Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2183

Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

9:00AM-11:00AM: Abstract Number: 1859

Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2124

Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

9:00AM-11:00AM: Abstract Number: 1790

Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2267

Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2157

Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis

9:00AM-11:00AM: Abstract Number: 1740

Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers

9:00AM-11:00AM: Abstract Number: 2020

Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice

9:00AM-11:00AM: Abstract Number: 2218

Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1830

Exploring Psychosocial Characteristics of Youth with Chronic Pain Across Gender Identities

9:00AM-11:00AM: Abstract Number: 1825

Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada

9:00AM-11:00AM: Abstract Number: 2424

Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project

9:00AM-11:00AM: Abstract Number: 1719

Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway

9:00AM-11:00AM: Abstract Number: 1791

Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622

9:00AM-11:00AM: Abstract Number: 2065

Exploring the Power of Ultrasound in Rheumatology: Insights from Young Rheumatologists in Mexico

9:00AM-11:00AM: Abstract Number: 1988

Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis

9:00AM-11:00AM: Abstract Number: 2220

Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort

9:00AM-11:00AM: Abstract Number: 1800

Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2270

Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study

9:00AM-11:00AM: Abstract Number: 1797

Factors Associated with Distress Related to Perceived Dignity in Patients with Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1722

Fate-mapping of Synovial Monocytes and Macrophages

9:00AM-11:00AM: Abstract Number: 1749

Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2398

FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 1869

FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients

9:00AM-11:00AM: Abstract Number: 2092

Feasibility and Efficacy of Culturally Appropriate Spanish Language-First Patient Education for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2196

Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)

9:00AM-11:00AM: Abstract Number: 1752

Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint

9:00AM-11:00AM: Abstract Number: 2199

Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 2339

Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies

9:00AM-11:00AM: Abstract Number: 2138

Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2117

Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1960

From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence

9:00AM-11:00AM: Abstract Number: 2086

From Fellow to Fellowship Director: Gender Equity in Pediatric Rheumatology Pipeline

9:00AM-11:00AM: Abstract Number: 2312

Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2247

Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2217

Gender Disparities in Disease Activity Scores and Treatment Response Among Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2016

Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis

9:00AM-11:00AM: Abstract Number: 1710

Genetic Associations in Juvenile Idiopathic Arthritis Determined with an Electronic Health Record Based Approach

9:00AM-11:00AM: Abstract Number: 2115

Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1817

Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER

9:00AM-11:00AM: Abstract Number: 2415

Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study

9:00AM-11:00AM: Abstract Number: 2141

Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)

9:00AM-11:00AM: Abstract Number: 2032

Goal Concordance in Rheumatoid Arthritis Patients with Depression – What Do Patients Prioritize?

9:00AM-11:00AM: Abstract Number: 1793

Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis

9:00AM-11:00AM: Abstract Number: 2241

Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

9:00AM-11:00AM: Abstract Number: 2236

Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2232

Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23

9:00AM-11:00AM: Abstract Number: 1774

Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1730

Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2081

Harnessing the Power of Social Media for Good: Using Instagram as a Formative Assessment Tool

9:00AM-11:00AM: Abstract Number: 2351

Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years

9:00AM-11:00AM: Abstract Number: 2029

Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?

9:00AM-11:00AM: Abstract Number: 1851

Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

9:00AM-11:00AM: Abstract Number: 1899

Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States

9:00AM-11:00AM: Abstract Number: 1983

Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial

9:00AM-11:00AM: Abstract Number: 2216

Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study

9:00AM-11:00AM: Abstract Number: 2352

High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1716

High-Throughput Semi-Automated Micro-CT Analysis Identifies the Cuboid Bone as a Sex-Dependent Biomarker of Inflammatory-Erosive Arthritis in TNF-Tg Mice

9:00AM-11:00AM: Abstract Number: 1823

Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia

9:00AM-11:00AM: Abstract Number: 1936

Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry

9:00AM-11:00AM: Abstract Number: 2128

Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1744

Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission

9:00AM-11:00AM: Abstract Number: 1858

How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?

9:00AM-11:00AM: Abstract Number: 2226

How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries

9:00AM-11:00AM: Abstract Number: 1994

How Is Paracetamol Prescribed in Low Back Pain and Osteoarthritis in France? Paracetamol Prescription Patterns in the Real-World General Practice

9:00AM-11:00AM: Abstract Number: 1998

How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C

9:00AM-11:00AM: Abstract Number: 1724

Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects

9:00AM-11:00AM: Abstract Number: 1852

Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2343

Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications

9:00AM-11:00AM: Abstract Number: 2327

Hydroxychloroquine Improves Low Complement Levels

9:00AM-11:00AM: Abstract Number: 1816

Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver

9:00AM-11:00AM: Abstract Number: 1807

Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty

9:00AM-11:00AM: Abstract Number: 1712

Identification and Functional Characterization of Eight CANDLE/PRAAS Causing Proteasome Variants in Five Unrelated Patients

9:00AM-11:00AM: Abstract Number: 2213

Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach

9:00AM-11:00AM: Abstract Number: 1758

Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1738

Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2362

Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2336

Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis

9:00AM-11:00AM: Abstract Number: 1941

Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations

9:00AM-11:00AM: Abstract Number: 1909

Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease

9:00AM-11:00AM: Abstract Number: 2235

Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2262

Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study

9:00AM-11:00AM: Abstract Number: 2322

Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State

9:00AM-11:00AM: Abstract Number: 1792

Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1943

IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria

9:00AM-11:00AM: Abstract Number: 2058

IL-1 Blocking Treatment Slows the Progression of Sensorineural Hearing Loss in Patients with NOMID

9:00AM-11:00AM: Abstract Number: 1882

Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations

9:00AM-11:00AM: Abstract Number: 1863

Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion

9:00AM-11:00AM: Abstract Number: 2407

Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1732

Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA)

9:00AM-11:00AM: Abstract Number: 2386

Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2038

Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients

9:00AM-11:00AM: Abstract Number: 2397

Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1993

Impact of Metabolic Syndrome on Ultrasonographic Findings and Quality of Life in Patients with Early Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1912

Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System

9:00AM-11:00AM: Abstract Number: 2113

Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies

9:00AM-11:00AM: Abstract Number: 1924

Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD

9:00AM-11:00AM: Abstract Number: 1849

Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1970

Impaired Health-Related Quality of Life in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Analysis from the COVAD Dataset

9:00AM-11:00AM: Abstract Number: 2080

Implementation of a Clinically-Focused Online Journal Club in Rheumatology: Experience from TheMednet

9:00AM-11:00AM: Abstract Number: 2046

Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 1905

Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic

9:00AM-11:00AM: Abstract Number: 1906

Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1925

Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study

9:00AM-11:00AM: Abstract Number: L06

Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT)

9:00AM-11:00AM: Abstract Number: 2006

Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic

9:00AM-11:00AM: Abstract Number: 1856

Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1902

Improving the Sharing of Information from Reviews of Measurement Properties: The OMERACT Summary of Measurement Properties (SOMP) Table

9:00AM-11:00AM: Abstract Number: 1708

In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity

9:00AM-11:00AM: Abstract Number: 1897

In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care

9:00AM-11:00AM: Abstract Number: 2012

Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab

9:00AM-11:00AM: Abstract Number: 2348

Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

9:00AM-11:00AM: Abstract Number: 2363

Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications

9:00AM-11:00AM: Abstract Number: 2206

Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2178

Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2388

Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study

9:00AM-11:00AM: Abstract Number: 2282

Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19

9:00AM-11:00AM: Abstract Number: 2094

Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator

9:00AM-11:00AM: Abstract Number: 2120

Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections

9:00AM-11:00AM: Abstract Number: 2229

Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies

9:00AM-11:00AM: Abstract Number: 1743

Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies

9:00AM-11:00AM: Abstract Number: 2305

Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1967

Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment

9:00AM-11:00AM: Abstract Number: 2103

Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1766

Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2417

Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study

9:00AM-11:00AM: Abstract Number: 1847

Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1978

Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2095

Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1773

Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity

9:00AM-11:00AM: Abstract Number: 2068

Integration of Basic Science into Virtual Patient Cases to Enhance Clinical Reasoning Skills

9:00AM-11:00AM: Abstract Number: 1783

Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1875

Inter and Intra-observer Reliability of Assessment for Nailfold Capillary Abnormalities in Rheumatic Patients with Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2297

Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2078

Interim Evaluation of a 6 Year Remote Online Adaptive Learning Platform Module for Rheumatology Fellows: Applied Rheumatology on the Go

9:00AM-11:00AM: Abstract Number: 2212

Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2035

Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 2042

Intraocular Cytokine Profiling of Autoimmune Uveitis

9:00AM-11:00AM: Abstract Number: 1914

Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes

9:00AM-11:00AM: Abstract Number: 1966

Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?

9:00AM-11:00AM: Abstract Number: 2369

Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients

9:00AM-11:00AM: Abstract Number: 1826

Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada

9:00AM-11:00AM: Abstract Number: 2031

Involving Patients Research Partners in Research in Rheumatology: Where Do We Stand? A Scoping Review of Recent Randomized Controlled Trials and Translational Science Studies

9:00AM-11:00AM: Abstract Number: 2242

Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes

9:00AM-11:00AM: Abstract Number: 1865

Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative

9:00AM-11:00AM: Abstract Number: 2292

Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?

9:00AM-11:00AM: Abstract Number: 2354

Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?

9:00AM-11:00AM: Abstract Number: 2368

Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes

9:00AM-11:00AM: Abstract Number: 2102

Is This Prosthetic Joint Infected or Flaring?

9:00AM-11:00AM: Abstract Number: 2231

Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2174

JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib

9:00AM-11:00AM: Abstract Number: 1761

JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2413

Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review

9:00AM-11:00AM: Abstract Number: 2207

Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States

9:00AM-11:00AM: Abstract Number: 2387

Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study

9:00AM-11:00AM: Abstract Number: 2099

Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan

9:00AM-11:00AM: Abstract Number: 2324

Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study

9:00AM-11:00AM: Abstract Number: 2137

Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics

9:00AM-11:00AM: Abstract Number: 2166

Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study

9:00AM-11:00AM: Abstract Number: 1868

Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial

9:00AM-11:00AM: Abstract Number: 2225

Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)

9:00AM-11:00AM: Abstract Number: 1850

Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data

9:00AM-11:00AM: Abstract Number: 2325

Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1805

Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake

9:00AM-11:00AM: Abstract Number: 2271

Longitudinal Changes in Type 1 & Type 2 SLE Activity

9:00AM-11:00AM: Abstract Number: 2238

Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study

9:00AM-11:00AM: Abstract Number: 1718

Longitudinal Quantification of Bone Erosions, Pulmonary Disease, Pain, Gait and Sarcopenia to Holistically Assess Decreased Ad Libitum Physical Activity and Effects of Exercise in the TNF-Transgenic Murine Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2378

Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort

9:00AM-11:00AM: Abstract Number: 2188

Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis

9:00AM-11:00AM: Abstract Number: 2265

Lupus Damage Index Revision – Item Generation and Reduction Phase

9:00AM-11:00AM: Abstract Number: 2275

Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody

9:00AM-11:00AM: Abstract Number: 2274

Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse

9:00AM-11:00AM: Abstract Number: 2017

Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2189

Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement

9:00AM-11:00AM: Abstract Number: 2310

Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models

9:00AM-11:00AM: Abstract Number: 1785

Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis

9:00AM-11:00AM: Abstract Number: 1748

Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

9:00AM-11:00AM: Abstract Number: 1776

Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression

9:00AM-11:00AM: Abstract Number: 2422

Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial)

9:00AM-11:00AM: Abstract Number: 2384

Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group

9:00AM-11:00AM: Abstract Number: 2059

Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra

9:00AM-11:00AM: Abstract Number: 1927

Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1739

Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies

9:00AM-11:00AM: Abstract Number: 2057

Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2299

Medication-related Hospitalizations in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2093

Meeting the Educational and Language Needs of the Lupus Community: A Snapshot of 2022 Lupus Inquiries

9:00AM-11:00AM: Abstract Number: 2287

Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic

9:00AM-11:00AM: Abstract Number: 2268

Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study

9:00AM-11:00AM: Abstract Number: 1760

Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation

9:00AM-11:00AM: Abstract Number: 1789

Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion

9:00AM-11:00AM: Abstract Number: 2182

Mitochondrial Alterations in Primary Sjögren´s Syndrome

9:00AM-11:00AM: Abstract Number: 2342

Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial

9:00AM-11:00AM: Abstract Number: 2331

Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2044

Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population

9:00AM-11:00AM: Abstract Number: 1857

More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen)

9:00AM-11:00AM: Abstract Number: 1953

Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019

9:00AM-11:00AM: Abstract Number: 1980

Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1866

MRI Confirms MRE Evidence of Sacroiliitis in Many with Crohn’s Disease: A Prospective Study for the Screening of axSpA in High-risk Populations

9:00AM-11:00AM: Abstract Number: 1878

MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study

9:00AM-11:00AM: Abstract Number: 1795

Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis

9:00AM-11:00AM: Abstract Number: 2340

Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1969

Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study

9:00AM-11:00AM: Abstract Number: 1971

Muscle Pathology in Patients with Primary Biliary Cholangitis

9:00AM-11:00AM: Abstract Number: L02

Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE

9:00AM-11:00AM: Abstract Number: 1947

National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England

9:00AM-11:00AM: Abstract Number: 1918

Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality

9:00AM-11:00AM: Abstract Number: 2069

Navigating the Residency-to-Fellowship Transition in Rheumatology

9:00AM-11:00AM: Abstract Number: 2186

Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life

9:00AM-11:00AM: Abstract Number: 1913

Neurosarcoidosis Disease Epidemiology. University Hospital in Northern Spain 1999-2019

9:00AM-11:00AM: Abstract Number: 2358

Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma

9:00AM-11:00AM: Abstract Number: 2233

Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 2192

New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology

9:00AM-11:00AM: Abstract Number: 2118

New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry

9:00AM-11:00AM: Abstract Number: 1786

Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1957

Non-Linear Mendelian Randomization Analyses Support a Role for Low Vitamin D Status in Sarcopenia Risk

9:00AM-11:00AM: Abstract Number: 1754

Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19

9:00AM-11:00AM: Abstract Number: 2150

Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients

9:00AM-11:00AM: Abstract Number: 2163

Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?

9:00AM-11:00AM: Abstract Number: 1999

One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation

9:00AM-11:00AM: Abstract Number: 2421

Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2361

Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2294

Organ Damage Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 2025

Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis

9:00AM-11:00AM: Abstract Number: 2257

Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)

9:00AM-11:00AM: Abstract Number: 2300

Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network

9:00AM-11:00AM: Abstract Number: 2073

Outcomes of the First Year of a Rheumatology Curriculum at Two Internal Medicine Residency Programs

9:00AM-11:00AM: Abstract Number: 2345

Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2100

Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1898

Patient After Visit Instructions at a University Rheumatology Outpatient Clinic: Do They Make a Difference?

9:00AM-11:00AM: Abstract Number: 2276

Patient Reported Impact of Lupus on Quality of Life

9:00AM-11:00AM: Abstract Number: 2024

Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials

9:00AM-11:00AM: Abstract Number: 2277

Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences

9:00AM-11:00AM: Abstract Number: 2145

Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study

9:00AM-11:00AM: Abstract Number: 1707

PD1-Expressing Regulatory T Cells Found in Inflamed Joints Suppress Tph Cell-B Cell Interactions

9:00AM-11:00AM: Abstract Number: 2056

Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 1964

Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization

9:00AM-11:00AM: Abstract Number: 1803

Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress

9:00AM-11:00AM: Abstract Number: 2064

Perceptions of Rheumatology Fellows on Mentorship Quality After Implementation of a Formalized Mentorship Program

9:00AM-11:00AM: Abstract Number: 1872

Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients

9:00AM-11:00AM: Abstract Number: 1880

Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2126

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity

9:00AM-11:00AM: Abstract Number: 1867

Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography

9:00AM-11:00AM: Abstract Number: 2240

Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)

9:00AM-11:00AM: Abstract Number: 1765

Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives

9:00AM-11:00AM: Abstract Number: 2302

Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2144

Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

9:00AM-11:00AM: Abstract Number: 2161

Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501

9:00AM-11:00AM: Abstract Number: 2043

Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease

9:00AM-11:00AM: Abstract Number: 2112

Physical Activity in a Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2076

Piloting a Rheumatology and Sports Medicine Case-Based Collaborative Learning Curriculum for Medical Students

9:00AM-11:00AM: Abstract Number: 1804

Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women

9:00AM-11:00AM: Abstract Number: 2371

Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1733

Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2160

Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes

9:00AM-11:00AM: Abstract Number: 1934

Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis

9:00AM-11:00AM: Abstract Number: 2030

Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History

9:00AM-11:00AM: Abstract Number: 1828

Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission

9:00AM-11:00AM: Abstract Number: 1935

Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19

9:00AM-11:00AM: Abstract Number: 2011

Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis

9:00AM-11:00AM: Abstract Number: 2320

Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2273

Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine

9:00AM-11:00AM: Abstract Number: 2053

Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis

9:00AM-11:00AM: Abstract Number: 2295

Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2278

Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry

9:00AM-11:00AM: Abstract Number: 1968

Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population

9:00AM-11:00AM: Abstract Number: 1985

Preliminary Results for the Total Knee Replacement Coaching Program for Patients Preparing to Undergo Total Knee Arthroplasty, a Pilot Randomized Trial

9:00AM-11:00AM: Abstract Number: 2209

Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study

9:00AM-11:00AM: Abstract Number: 1923

Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre

9:00AM-11:00AM: Abstract Number: 2130

Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab

9:00AM-11:00AM: Abstract Number: 1942

Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases

9:00AM-11:00AM: Abstract Number: 1832

Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital

9:00AM-11:00AM: Abstract Number: 1713

Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model

9:00AM-11:00AM: Abstract Number: 2248

Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1751

Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls

9:00AM-11:00AM: Abstract Number: 2264

Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes

9:00AM-11:00AM: Abstract Number: 2355

Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension

9:00AM-11:00AM: Abstract Number: 1864

Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points

9:00AM-11:00AM: Abstract Number: 1757

Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity

9:00AM-11:00AM: Abstract Number: 1959

Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2087

Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline

9:00AM-11:00AM: Abstract Number: 2091

Reach and Representativeness of Participants in an Evidence-Based, Community-Delivered Physical Activity Intervention in Adults with Arthritis

9:00AM-11:00AM: Abstract Number: 2175

Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study

9:00AM-11:00AM: Abstract Number: 2164

Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 2109

Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2246

Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan

9:00AM-11:00AM: Abstract Number: 2395

Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group

9:00AM-11:00AM: Abstract Number: 2293

Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease

9:00AM-11:00AM: Abstract Number: 1705

Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients

9:00AM-11:00AM: Abstract Number: 1917

Reducing Inadvertent Antifilarial Antibody Testing at an Academic Medical Center: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 1842

Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center

9:00AM-11:00AM: Abstract Number: 2195

Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)

9:00AM-11:00AM: Abstract Number: 1787

Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease

9:00AM-11:00AM: Abstract Number: 2414

Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors

9:00AM-11:00AM: Abstract Number: 2301

Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years

9:00AM-11:00AM: Abstract Number: 2382

Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis

9:00AM-11:00AM: Abstract Number: 1949

Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis

9:00AM-11:00AM: Abstract Number: 2104

Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2223

Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study

9:00AM-11:00AM: Abstract Number: 2334

Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

9:00AM-11:00AM: Abstract Number: 2380

Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data

9:00AM-11:00AM: Abstract Number: 2204

Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)

9:00AM-11:00AM: Abstract Number: 1928

Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 1955

Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 2159

Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic

9:00AM-11:00AM: Abstract Number: 2338

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2359

Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1827

Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device

9:00AM-11:00AM: Abstract Number: 2110

Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers

9:00AM-11:00AM: Abstract Number: 1772

Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients

9:00AM-11:00AM: Abstract Number: 1802

Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database

9:00AM-11:00AM: Abstract Number: 2260

Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2052

Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: L11

Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study

9:00AM-11:00AM: Abstract Number: 2406

Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study

9:00AM-11:00AM: Abstract Number: 2385

Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2116

Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 1956

Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1778

Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2353

Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

9:00AM-11:00AM: Abstract Number: 2405

Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1771

Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases

9:00AM-11:00AM: Abstract Number: 2088

Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline

9:00AM-11:00AM: Abstract Number: 1759

Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1892

Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study

9:00AM-11:00AM: Abstract Number: 1796

Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)

9:00AM-11:00AM: Abstract Number: 2147

Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East

9:00AM-11:00AM: Abstract Number: 2162

Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure

9:00AM-11:00AM: Abstract Number: 2337

Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2047

Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience

9:00AM-11:00AM: Abstract Number: 2190

Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2180

Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome

9:00AM-11:00AM: Abstract Number: 1915

Scleritis and Development of Autoimmune Disease: A Case Series

9:00AM-11:00AM: Abstract Number: 2288

Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set

9:00AM-11:00AM: Abstract Number: 2129

SCORE and SCORE2 Comparison in Cardiovascular Risk Estimation in Rheumatoid Arthritis Patients: A Cross-sectional Study Including Carotid Ultrasound

9:00AM-11:00AM: Abstract Number: 2009

Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients

9:00AM-11:00AM: Abstract Number: 2051

Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm

9:00AM-11:00AM: Abstract Number: 2005

Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users

9:00AM-11:00AM: Abstract Number: 2181

Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients

9:00AM-11:00AM: Abstract Number: 1907

Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains

9:00AM-11:00AM: Abstract Number: 2349

Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2203

Self-Reported and Physician´s Assessment of Inflammatory Back Pain According to ASAS Criteria: Is It the Same?

9:00AM-11:00AM: Abstract Number: 2111

Self-reported Methotrexate Adherence Underestimates Biochemical Adherence: Results from the Methotrexate Use Improvement in Rheumatoid Arthritis Using Biomarker Feedback Trial

9:00AM-11:00AM: Abstract Number: 2200

Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort

9:00AM-11:00AM: Abstract Number: 2119

Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2140

Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1734

Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin

9:00AM-11:00AM: Abstract Number: 2420

Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry

9:00AM-11:00AM: Abstract Number: 2033

Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication

9:00AM-11:00AM: Abstract Number: 1989

Shared Variation Among Cartilage Thickness Change Maps and Baseline Clinical Features at the Initiation of Structural Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 2289

Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

9:00AM-11:00AM: Abstract Number: 1862

Significant Overlap of Inflammatory and Degenerative Features on Spinal Imaging Among Patients with Degenerative Spinal Disease, Diffuse Idiopathic Skeletal Hyperostosis and Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1814

Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry

9:00AM-11:00AM: Abstract Number: 1762

Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

9:00AM-11:00AM: Abstract Number: 1939

Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity

9:00AM-11:00AM: Abstract Number: 2373

SIRPα Expression in Systemic Vasculitis

9:00AM-11:00AM: Abstract Number: 2346

SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

9:00AM-11:00AM: Abstract Number: 2298

SLE Patients Are at High Risk for Tuberculosis Infection: Data from a Lupus Center of an Endemic Country

9:00AM-11:00AM: Abstract Number: 1746

Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies

9:00AM-11:00AM: Abstract Number: 2107

Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study

9:00AM-11:00AM: Abstract Number: 2089

Social Listening Analysis of IgG4-Related Disease Social Media Discussions

9:00AM-11:00AM: Abstract Number: 2279

Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2372

Soluble Triggering Receptor Expressed on Myeloid Cell-1 Reflects the Cross-sectional Activity of Microscopic Polyangiitis and Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1888

Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy

9:00AM-11:00AM: Abstract Number: 2341

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2366

Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma

9:00AM-11:00AM: Abstract Number: 2108

Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH)

9:00AM-11:00AM: Abstract Number: 1742

Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

9:00AM-11:00AM: Abstract Number: 1820

Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study

9:00AM-11:00AM: Abstract Number: 1811

Strong Relationships Between Body Component Changes and Serum Uric Acid Variability

9:00AM-11:00AM: Abstract Number: 2404

Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk

9:00AM-11:00AM: Abstract Number: 2172

Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients

9:00AM-11:00AM: Abstract Number: 1720

Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2054

Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience

9:00AM-11:00AM: Abstract Number: 2152

Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study

9:00AM-11:00AM: Abstract Number: 2036

Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters

9:00AM-11:00AM: Abstract Number: 2244

Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2015

Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases

9:00AM-11:00AM: Abstract Number: 2135

Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression

9:00AM-11:00AM: Abstract Number: 2214

Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1896

Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale

9:00AM-11:00AM: Abstract Number: 2132

Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates

9:00AM-11:00AM: Abstract Number: 2170

Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study

9:00AM-11:00AM: Abstract Number: 2286

Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach

9:00AM-11:00AM: Abstract Number: 2360

Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway

9:00AM-11:00AM: Abstract Number: 2403

Systole and Diastole Ultrasound Wall Thickness Shows Significant Differences That Affect the Diagnosis and Assessment of Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1709

Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction

9:00AM-11:00AM: Abstract Number: 2344

Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study

9:00AM-11:00AM: Abstract Number: 1883

Thalamocortical Mechanisms of a Remote Mind-body Intervention for Knee Osteoarthritis Pain

9:00AM-11:00AM: Abstract Number: 1821

The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage

9:00AM-11:00AM: Abstract Number: 1932

The Association Between Initial Ferritin and Complications from Adults Onset Stills Disease and Intensive Care Unit Admission

9:00AM-11:00AM: Abstract Number: 2308

The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort

9:00AM-11:00AM: Abstract Number: 2318

The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1981

The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up

9:00AM-11:00AM: Abstract Number: 1815

The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register

9:00AM-11:00AM: Abstract Number: 1838

The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility

9:00AM-11:00AM: Abstract Number: 1768

The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study

9:00AM-11:00AM: Abstract Number: 1736

The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis

9:00AM-11:00AM: Abstract Number: 1777

The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function

9:00AM-11:00AM: Abstract Number: 2254

The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 2259

The Effects of Systematic Lupus Erythematosus Related Cognitive Impairments on Activities of Daily Living and Life Role Participation: A Qualitative Framework Study

9:00AM-11:00AM: Abstract Number: 1788

The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis

9:00AM-11:00AM: Abstract Number: 1822

The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)

9:00AM-11:00AM: Abstract Number: 1885

The Frequency and Importance of Subchondral Radius Cysts in Rheumatoid Arthritis Patients Under B/tsDMARDs

9:00AM-11:00AM: Abstract Number: 2377

The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2256

The Impact of Clinical Trial Metrics in Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2155

The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies

9:00AM-11:00AM: Abstract Number: 2075

The Impact of Rheumatology Fellow Initiated Curriculum Design on Resident Education

9:00AM-11:00AM: Abstract Number: 2227

The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1948

The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 2357

The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2280

The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 1741

The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1775

The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline

9:00AM-11:00AM: Abstract Number: 2168

The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1806

The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2114

The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function

9:00AM-11:00AM: Abstract Number: 2014

The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis

9:00AM-11:00AM: Abstract Number: 1794

The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1782

The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation

9:00AM-11:00AM: Abstract Number: 1721

The Therapeutic Effects of Gingival Mesenchymal Stem Cells and Their Exosomes in a Chimeric Model of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2408

The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts

9:00AM-11:00AM: Abstract Number: 2291

Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry

9:00AM-11:00AM: Abstract Number: 1726

Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1984

Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1991

Therapeutic Efficacy of Intra Articular Injection of Human Bone Marrow Derived Mesenchymal Stem Cells in Knee Osteoarthritis; Randomized, Double-blind, Placebo-controlled Clinical Trial

9:00AM-11:00AM: Abstract Number: 1950

Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study

9:00AM-11:00AM: Abstract Number: 2131

Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1801

Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1781

TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 1769

TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model

9:00AM-11:00AM: Abstract Number: 1767

TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation

9:00AM-11:00AM: Abstract Number: 1808

Tobacco Smoking Reduces the Incidence and Delays the Progression of Knee Osteoarthritis: 10-year Retrospective Cohort Study Based on Korea National Health Insurance Service-Health Screening Database

9:00AM-11:00AM: Abstract Number: 2410

Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients

9:00AM-11:00AM: Abstract Number: 1962

Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis

9:00AM-11:00AM: Abstract Number: 2374

Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1887

Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2063

Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers

9:00AM-11:00AM: Abstract Number: 2023

Transition Readiness over Time in a Rheumatology Transition Clinic

9:00AM-11:00AM: Abstract Number: 1904

Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs

9:00AM-11:00AM: Abstract Number: 2045

Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

9:00AM-11:00AM: Abstract Number: 2154

Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs

9:00AM-11:00AM: Abstract Number: 2243

Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 2066

Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy

9:00AM-11:00AM: Abstract Number: 2399

Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 1755

Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes

9:00AM-11:00AM: Abstract Number: 2237

Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2350

Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)

9:00AM-11:00AM: Abstract Number: 1926

Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1890

Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features

9:00AM-11:00AM: Abstract Number: 1922

Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

9:00AM-11:00AM: Abstract Number: 1855

Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia

9:00AM-11:00AM: Abstract Number: 1911

Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study

9:00AM-11:00AM: Abstract Number: 1889

Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 2072

Utility of a Novel Pediatric Rheumatology Interactive Teleconference Series: Rheum2Play

9:00AM-11:00AM: Abstract Number: 1871

Utility of Infrared Thermography in Patients with Digital Gangrene

9:00AM-11:00AM: Abstract Number: 2313

Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2049

Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls

9:00AM-11:00AM: Abstract Number: 2285

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update

9:00AM-11:00AM: Abstract Number: 1951

Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis

9:00AM-11:00AM: Abstract Number: 1958

Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study

9:00AM-11:00AM: Abstract Number: 1839

Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting

9:00AM-11:00AM: Abstract Number: 1840

Value of Various Intra-Articular Injections for Knee Osteoarthritis Management

9:00AM-11:00AM: Abstract Number: 2050

Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey

9:00AM-11:00AM: Abstract Number: 1996

Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics

9:00AM-11:00AM: Abstract Number: 2419

Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry

9:00AM-11:00AM: Abstract Number: 1979

Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis

9:00AM-11:00AM: Abstract Number: 1854

What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort

9:00AM-11:00AM: Abstract Number: 2201

When Usual Care Is Not so Usual: Facing the Challenges of Protocol Violations and Generalisability When Running a Strategy Trial. the Example of the Cluster-Randomized TICOSPA Trial

9:00AM-11:00AM: Abstract Number: 1901

Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 1884

Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?

9:00AM-11:00AM: Abstract Number: 2198

Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

9:00AM-11:00AM: Abstract Number: 2173

Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients

9:00AM-11:00AM: Abstract Number: 1973

Work-related Impact in Young Patients with Chronic Back Pain Awaiting a Magnetic Resonance Imaging

9:00AM-11:00AM: Abstract Number: 1946

Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis

11:00AM-12:30PM: Abstract Number: 2427

Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis

11:00AM-12:30PM: Abstract Number: 2425

Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data

11:00AM-12:30PM: Abstract Number: 2429

Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial

11:00AM-12:30PM: Abstract Number: 2426

The Role of β-catenin in Synovial Lining Fibroblast Differentiation

11:00AM-12:30PM: Abstract Number: 2430

Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

11:00AM-12:30PM: Abstract Number: 2428

Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors

2:00PM-3:30PM: Abstract Number: 2473

A Consensus Based Algorithm to Screen for Lung Disease in Children with Systemic Juvenile Idiopathic Arthritis

2:00PM-3:30PM: Abstract Number: 2434

Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response

2:00PM-3:30PM: Abstract Number: 2455

Addressing Native American Health Disparities in Rheumatoid Arthritis by Training Primary Care Providers: Expanding the Reach of the RAE Initiative

2:00PM-3:30PM: Abstract Number: 2457

Ageism in Rheumatology: The Health Care Professional’s Perspective

2:00PM-3:30PM: Abstract Number: 2491

Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort

2:00PM-3:30PM: Abstract Number: 2477

Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies

2:00PM-3:30PM: Abstract Number: 2452

Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System

2:00PM-3:30PM: Abstract Number: 2468

Association Between Gut Microbiome-related Metabolites and Symptomatic Hand Osteoarthritis in Two Independent Cohorts

2:00PM-3:30PM: Abstract Number: 2469

Associations Between Body Composition Measurements of Obesity and the Radiographic Progression of Hand Osteoarthritis: Data from the Dong-gu Study

2:00PM-3:30PM: Abstract Number: 2464

B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature

2:00PM-3:30PM: Abstract Number: 2443

Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 2483

CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort

2:00PM-3:30PM: Abstract Number: 2436

Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis

2:00PM-3:30PM: Abstract Number: 2465

Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen

2:00PM-3:30PM: Abstract Number: 2449

Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study

2:00PM-3:30PM: Abstract Number: 2485

Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 2494

Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis

2:00PM-3:30PM: Abstract Number: 2489

Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE

2:00PM-3:30PM: Abstract Number: 2435

Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics

2:00PM-3:30PM: Abstract Number: 2476

Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score

2:00PM-3:30PM: Abstract Number: 2480

Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI

2:00PM-3:30PM: Abstract Number: 2453

Development of a Hydroxychloroquine Retinopathy Prediction Score

2:00PM-3:30PM: Abstract Number: 2444

Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis

2:00PM-3:30PM: Abstract Number: 2498

Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

2:00PM-3:30PM: Abstract Number: 2478

Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 2488

Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial

2:00PM-3:30PM: Abstract Number: 2463

Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients

2:00PM-3:30PM: Abstract Number: 2475

Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders

2:00PM-3:30PM: Abstract Number: 2454

Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study

2:00PM-3:30PM: Abstract Number: 2497

Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 2450

Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 2460

Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus

2:00PM-3:30PM: Abstract Number: 2471

Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts

2:00PM-3:30PM: Abstract Number: 2496

HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression

2:00PM-3:30PM: Abstract Number: 2499

Influence of Adiposity on Physical Function, Physical Activity, and Self-Reported Symptom Severity for Individuals with Arthritis Prior to Beginning a Physical Activity Promotion Intervention

2:00PM-3:30PM: Abstract Number: 2431

Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages

2:00PM-3:30PM: Abstract Number: 2447

Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus

2:00PM-3:30PM: Abstract Number: 2446

Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 2433

Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells

2:00PM-3:30PM: Abstract Number: 2470

Low Serum Adiponectin Levels Were Associated with Radiographic Progression of Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study

2:00PM-3:30PM: Abstract Number: 2456

Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients

2:00PM-3:30PM: Abstract Number: 2462

Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications

2:00PM-3:30PM: Abstract Number: 2466

Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein

2:00PM-3:30PM: Abstract Number: 2442

Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis

2:00PM-3:30PM: Abstract Number: 2484

Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management

2:00PM-3:30PM: Abstract Number: 2487

Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity

2:00PM-3:30PM: Abstract Number: 2481

Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy

2:00PM-3:30PM: Abstract Number: 2482

Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis

2:00PM-3:30PM: Abstract Number: 2439

Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients

2:00PM-3:30PM: Abstract Number: 2467

Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging

2:00PM-3:30PM: Abstract Number: 2493

Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis

2:00PM-3:30PM: Abstract Number: 2459

Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals

2:00PM-3:30PM: Abstract Number: 2490

Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial

2:00PM-3:30PM: Abstract Number: 2501

Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity

2:00PM-3:30PM: Abstract Number: 2502

Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus

2:00PM-3:30PM: Abstract Number: 2486

Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?

2:00PM-3:30PM: Abstract Number: 2500

Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort

2:00PM-3:30PM: Abstract Number: 2440

Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 2438

Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function

2:00PM-3:30PM: Abstract Number: 2472

Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study

2:00PM-3:30PM: Abstract Number: 2445

Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis

2:00PM-3:30PM: Abstract Number: 2451

TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank

2:00PM-3:30PM: Abstract Number: 2492

The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

2:00PM-3:30PM: Abstract Number: 2458

The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center

2:00PM-3:30PM: Abstract Number: 2479

Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease

2:00PM-3:30PM: Abstract Number: 2461

Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies

2:00PM-3:30PM: Abstract Number: 2437

Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy

2:00PM-3:30PM: Abstract Number: 2495

Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

2:00PM-3:30PM: Abstract Number: 2441

Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis

2:00PM-3:30PM: Abstract Number: 2448

UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes

2:00PM-3:30PM: Abstract Number: 2474

Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience

2:00PM-3:30PM: Abstract Number: 2432

Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis

4:00PM-5:30PM: Abstract Number: 2534

A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement

4:00PM-5:30PM: Abstract Number: 2519

A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease

4:00PM-5:30PM: Abstract Number: 2546

Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up

4:00PM-5:30PM: Abstract Number: 2558

Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab

4:00PM-5:30PM: Abstract Number: 2510

Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

4:00PM-5:30PM: Abstract Number: 2539

Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA

4:00PM-5:30PM: Abstract Number: 2547

Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study

4:00PM-5:30PM: Abstract Number: 2508

Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts

4:00PM-5:30PM: Abstract Number: 2543

Clinical and Radiographic Results of Tapering and Withdrawing CsDMARDs versus Stable Treatment in Patients with Rheumatoid Arthritis in Remission: 3-year Results from a Randomized Controlled Trial

4:00PM-5:30PM: Abstract Number: 2559

Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis

4:00PM-5:30PM: Abstract Number: 2557

Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades

4:00PM-5:30PM: Abstract Number: 2555

Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction

4:00PM-5:30PM: Abstract Number: 2529

Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

4:00PM-5:30PM: Abstract Number: 2525

Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain

4:00PM-5:30PM: Abstract Number: 2518

Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach

4:00PM-5:30PM: Abstract Number: 2528

Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States

4:00PM-5:30PM: Abstract Number: 2503

Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes

4:00PM-5:30PM: Abstract Number: 2522

Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study

4:00PM-5:30PM: Abstract Number: 2541

Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity

4:00PM-5:30PM: Abstract Number: 2505

Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders

4:00PM-5:30PM: Abstract Number: 2536

DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection

4:00PM-5:30PM: Abstract Number: 2549

Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT

4:00PM-5:30PM: Abstract Number: 2545

Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study

4:00PM-5:30PM: Abstract Number: 2556

End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort

4:00PM-5:30PM: Abstract Number: 2520

Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis

4:00PM-5:30PM: Abstract Number: 2562

Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study

4:00PM-5:30PM: Abstract Number: 2542

Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

4:00PM-5:30PM: Abstract Number: 2537

Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs

4:00PM-5:30PM: Abstract Number: 2552

Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis

4:00PM-5:30PM: Abstract Number: 2513

Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

4:00PM-5:30PM: Abstract Number: 2548

Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials

4:00PM-5:30PM: Abstract Number: 2515

Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases

4:00PM-5:30PM: Abstract Number: 2544

Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo

4:00PM-5:30PM: Abstract Number: 2514

Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis

4:00PM-5:30PM: Abstract Number: 2532

Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts

4:00PM-5:30PM: Abstract Number: 2553

Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort

4:00PM-5:30PM: Abstract Number: 2531

Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids

4:00PM-5:30PM: Abstract Number: 2533

Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study

4:00PM-5:30PM: Abstract Number: 2523

Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty

4:00PM-5:30PM: Abstract Number: 2524

Relation of Pain Sensitivity to Forces While Walking in Adults with and Without Knee Pain: The Multicenter Osteoarthritis (MOST) Study

4:00PM-5:30PM: Abstract Number: 2551

Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis

4:00PM-5:30PM: Abstract Number: 2530

Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center

4:00PM-5:30PM: Abstract Number: 2509

Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias

4:00PM-5:30PM: Abstract Number: 2527

Risk Factors for Bone Loss in Systemic Lupus Erythematosus

4:00PM-5:30PM: Abstract Number: 2560

Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab

4:00PM-5:30PM: Abstract Number: 2506

Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation

4:00PM-5:30PM: Abstract Number: 2538

Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study

4:00PM-5:30PM: Abstract Number: 2526

Single-cell RNA Sequencing Reveals the CRTAC1+ Population Actively Contributes to the Pathogenesis of Spinal Ligament Degeneration by Inducing Macrophage Activation

4:00PM-5:30PM: Abstract Number: 2535

Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management

4:00PM-5:30PM: Abstract Number: 2511

Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies

4:00PM-5:30PM: Abstract Number: 2512

Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis

4:00PM-5:30PM: Abstract Number: 2504

The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b

4:00PM-5:30PM: Abstract Number: 2516

The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica

4:00PM-5:30PM: Abstract Number: 2550

The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis

4:00PM-5:30PM: Abstract Number: 2540

The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response

4:00PM-5:30PM: Abstract Number: 2561

The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group

4:00PM-5:30PM: Abstract Number: 2517

The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

4:00PM-5:30PM: Abstract Number: 2521

Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?

4:00PM-5:30PM: Abstract Number: 2554

Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort

4:00PM-5:30PM: Abstract Number: 2507

ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts

7:30AM-9:00AM: Abstract Number: L19

A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

7:30AM-9:00AM: Abstract Number: L15

AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography

7:30AM-9:00AM: Abstract Number: L18

Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands

7:30AM-9:00AM: Abstract Number: L17

Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study

7:30AM-9:00AM: Abstract Number: L20

Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study

7:30AM-9:00AM: Abstract Number: L16

Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial

9:00AM-10:30AM: Abstract Number: 2575

Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening

9:00AM-10:30AM: Abstract Number: 2567

An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases

9:00AM-10:30AM: Abstract Number: 2574

Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract

9:00AM-10:30AM: Abstract Number: 2572

Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival

9:00AM-10:30AM: Abstract Number: 2563

Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study

9:00AM-10:30AM: Abstract Number: 2566

Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database

9:00AM-10:30AM: Abstract Number: 2569

Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease

9:00AM-10:30AM: Abstract Number: 2568

First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients

9:00AM-10:30AM: Abstract Number: 2577

Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry

9:00AM-10:30AM: Abstract Number: 2580

High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis

9:00AM-10:30AM: Abstract Number: 2571

Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis

9:00AM-10:30AM: Abstract Number: 2578

Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles

9:00AM-10:30AM: Abstract Number: 2573

Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality

9:00AM-10:30AM: Abstract Number: 2576

Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study

9:00AM-10:30AM: Abstract Number: 2564

The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial

9:00AM-10:30AM: Abstract Number: 2565

The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021

9:00AM-10:30AM: Abstract Number: 2570

Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study

9:00AM-10:30AM: Abstract Number: 2579

Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies

11:00AM-12:30PM: Abstract Number: 2598

6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells

11:00AM-12:30PM: Abstract Number: 2586

A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis

11:00AM-12:30PM: Abstract Number: 2583

A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia

11:00AM-12:30PM: Abstract Number: 2595

A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)

11:00AM-12:30PM: Abstract Number: 2590

Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE)

11:00AM-12:30PM: Abstract Number: 2600

Clonal Hematopoiesis Is Associated with Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2585

Cytokine and Chemokine Elevations in ACPA+ Individuals Suggest Possible Viral, Mucosal and/or Innate Responses Are Related to the Transition to Future Clinical RA

11:00AM-12:30PM: Abstract Number: 2582

Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA

11:00AM-12:30PM: Abstract Number: 2597

Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial

11:00AM-12:30PM: Abstract Number: 2593

FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study

11:00AM-12:30PM: Abstract Number: 2584

Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis

11:00AM-12:30PM: Abstract Number: 2596

Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database

11:00AM-12:30PM: Abstract Number: 2601

Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning

11:00AM-12:30PM: Abstract Number: 2603

Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2587

Measuring Frailty in SLE: Agreement Among Methods

11:00AM-12:30PM: Abstract Number: 2604

Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis

11:00AM-12:30PM: Abstract Number: 2581

Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies

11:00AM-12:30PM: Abstract Number: 2589

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus

11:00AM-12:30PM: Abstract Number: 2602

Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2599

Study of the Role of interleukin-17 in Giant Cell Arteritis

11:00AM-12:30PM: Abstract Number: 2594

Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

11:00AM-12:30PM: Abstract Number: 2592

Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

11:00AM-12:30PM: Abstract Number: 2591

Under Assault: Ongoing Brain Dysfunction Identified on Resting State-functional MRI (rs-fMRI) in SLE Patients in Clinical Remission

11:00AM-12:30PM: Abstract Number: 2588

Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].